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Xiaobo Zhong
The research of my dissertation studies the methods of designing and analyzing
sequential multiple assignment randomized trial (SMART) for comparing multiple adap-
tive interventions. As a SMART typically consists of numerous adaptive interventions,
inferential procedures based on pairwise comparisons of all interventions may suffer sub-
stantial loss in power after accounting for multiplicity. I address this problem using two
approaches. First, I propose a likelihood-based Wald test, study the asymptotic distri-
bution of its test statistics, and apply it as a gate-keeping test for making an adaptive
intervention selection. Second, I consider a multiple comparison with the best approach
by constructing simultaneous confidence intervals that compare the interventions of in-
terest with the truly best intervention, which is assumed to be unknown in inference; an
adaptive intervention with the proposed interval excluding zero will be declared as infe-
rior to the truly best with a pre-specified confidence level. Simulation studies show that
both methods outperform the corresponding multiple comparison procedures based on
Bonferroni’s correction in terms of the power of test and the average width of confidence
intervals for estimation. Simulations also suggest desirable properties of the proposed
methods. I apply these methods to analyze two real data sets. As part of the disser-
tation, I also develop a user-friendly R software package that covers many statistical
work related to SMART, including study design, data analysis and visualization. Both
proposed methods can be implemented by using this R package. In the end of the dis-
sertation, I show an application of designing a SMART to compare multiple patient care
strategies for depression management based on one of the proposed methods.
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Chapter 1 Adaptive Intervention and SMART Design
My dissertation proposes methods for designing and analyzing randomized clinical trial,
specifically, sequential multiple assignment randomized trial (SMART), with the objective
to compare multiple adaptive interventions. I introduce in this chapter the background
and the motivation of my research. First, I introduce the concepts of adaptive interven-
tion in Chapter 1.1 and SMART in Chapter 1.2. And then I briefly compare SMART
with some other clinical trial designs that share some common features with SMART
in Chapter 1.3 . This chapter ends with the motivation of my dissertation research in
Chapter 1.4.
1.1 Adaptive Intervention
Personalized medicine, or called precision medicine, has become increasingly interest-
ing in statistical research in the past 2 decades. Although the concept of personalized
medicine varies by literatures and research communities, the basic idea is somehow in-
volving individual-level information in treatment selection (Kosorok, 2016). An adaptive
intervention (AI) is a multi-stage treatment strategy consisting of a sequence of treatment
selections, one per stage of treatment for a patient, which can be repeatedly adjusted ac-
cording to the individual’s ongoing clinical information, such as the treatment history and
the responses to the previous treatments. AIs have been widely used in managing chronic
diseases, such as cancer and depression, with the belief that the long-term response of an
individual can be optimized by adjusting the treatment selection as a function of time-
varying personalized data. Thus, it fits in the larger paradigm of personalized medicine
(Chakraborty and Murphy, 2014). There are multiple terms that have been used in liter-
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atures to describe such a multi-stage treatment strategy, including dynamics treatment
regime (Robins, 1986), adaptive treatment strategy (Lavori and Dawson, 2007; Mur-
phy, 2005), treatment policy (Lanceford, Davidian and Tsiatis, 2012; Wahed and Tsiatis,
2004), individualized treatment rule (Van der Lann and Peterson 2007), and adaptive
intervention (Collins, 2014). I use adaptive intervention in my dissertation.
Figure 1.1 gives an example of two-stage AI used for untreated diffuse large B-Cell
lymphoma (DLBCL) patients (Habermann et al., 2006). The goal is to help untreated
DLBCL patients to achieve durable complete remission. Under this AI, patients were first
given cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) at baseline
for 4 weeks as stage-1 treatment. At the end of Stage 1, an intermediate evaluation was
given to each patient and they were classified as respondents and non-respondents based
on the results of assessments. A patient who achieved complete remission (CR) or partial
remission (PR) within 4 weeks was classified as respondent and given Rituximab for
maintenance at Stage 2. On the other hand, a patient with stable disease, progression or
relapse was classified as non-respondent and given granulocyte colony-stimulating factor
(G-CSF) as supportive care at Stage 2. Comparing to a non-adaptive strategy that simply
gave patients CHOP followed by Rituximab or CHOP followed G-CSF, the treatment
selection at Stage 2 under this AI took into account the individual-level information
using the response to CHOP as surrogate, thus could potentially improve the long-term
health outcome of an individual. A patient under this AI could possibly follow one of
two treatment sequences indicated by the treatments selected and the response to stage-
1 treatment. One sequence was ”CHOP → response → Rituximab” and the other is
”CHOP → no response → G-CSF”. Which sequence was actually followed by a patient
depended on the value of intermediate outcome observed in clinical practice. In other
2
words, the treatment sequence received by a patient given an AI is completely specified














Stage-1 treatment Intermediate outcome Stage-2 treatment 
Figure 1.1 An adaptive intervention for patients with diffuse large B-cell lymphoma.
1.2 Sequential Multiple Assignment Randomized Trial
Sequential Multiple Assignment Randomized Trial (SMART) is the randomized clinical
trial (RCT) design that randomly assigns a collection of AIs to patients. Figure 1.2 is an
example of SMART design with the objective to compare 4 two-stage AIs for untreated
DLBCL patients (Habermann et al., 2006). Although CHOP has been considered as
the standard treatment for the front-line chemotherapy for untreated DLBCL patients, a
clinical investigation found that CHOP plus rituximab, a chimeric antibody that targeted
CD20 B cells, could potentially improve the overall response of the front-line therapy in
this population (Czuczman, Grillo-Lopez and White, 1999). Meanwhile, for those DL-
BCL patients who successfully achieved CR/PR in the front-line therapy, both rituximab
and observation are commonly used for maintenance in practice. In this trial, patients
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were first randomized to receive either CHOP or rituximab plus CHOP (R-CHOP) as
induction for 6-8 cycles at Stage 1. CR/PR patients who completed induction therapy
were randomly assigned to receive maintenance rituximab or observation for 6 months at
Stage 2, while those who failed to achieved CR/PR were given G-CSF as supportive care
according to the guideline of American Society of Clinical Oncology (American Society
of Clinical Oncology, 1996). A patient who completed this trial could followed one out
of 6 possible treatment sequences, including (1) “CHOP → Response → Rituximab”,
(2) ”CHOP → Response → Observation”, (3) CHOP → No response → G-CSF, (4)
”R-CHOP → Response → Rituximab”, (5) R-CHOP → Response → Observation, and
(6) R-CHOP→ No response→ G-CSF”, depending on the results of sequential random-
izations and the value of intermediate outcome observed on the patient. Consequently,
it provided data that allowed to compare 4 AIs. By virtue of sequential randomization,
the assumption of ignorable treatment holds in this case and thus the conclusion can be
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Figure 1.2. Two-stage SMART design for untreated DLBCL patients. CR: complete re-
mission; PR: partial remission; SD: stable disease; PROG: progression; REL: Relapse;
CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHOP: ritux-
imab plus CHOP ; G-CSF: granulocyte colony-stimulating factor.
SMART is an efficient design for early phase clinical trials when we are interested in
evaluating a collection of AIs. A common goal of such trials is to identify one promising or
several near-best candidates of AIs and move forward to a confirmatory study. Suppose
we are interested in evaluating the effects of 4 AIs that were defined in the DLBCL trial
(cf. Figure 1.2) and use a traditional RCT design that simply assigns patients randomly
to 4 independent groups at baseline, each of which corresponds to one AI of interest.
To obtain n patients for each AI, assuming equal randomization probabilities, we need
4n patients in total. However, by using a SMART design as shown in Figure 1.2, given
the same total sample size of 4n, we can have (1 + p)n patients for each AI, where p is
the response rate of stage-1 treatment. Another attractive feature of SMART is that the
sequential randomization provides data that allow to study multiple research questions.
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Because there are multiple randomization points, we can actually viewed SMART as a
combination of several small RCTs given different conditions, and thus use the data to
explore multiple secondary questions. For example, the design in Figure 1.2 provides data
that allow no only to compare 4 AIs, but also to make 3 other comparisons (1) CHOP
vs. R-CHOP at baseline, (2) maintenance rituximab vs. observation for patients who
responded to CHOP, and (3) maintenance rituximab vs. observation for patients who
responded to R-CHOP. The reason I called these “secondary” research questions is that
I assume the sample size calculation of this SMART is based on the primary question of
comparing 4 AIs. Thus, it may not have enough sample sizes to achieve certain powers
under the strictly controls of the targeted error rates for other questions. But the design
itself still provides valuable information for these questions. My dissertation research
focuses on the methods for comparing multiple AIs embedded in SMART, which are
applied to early phase trials with the objective to collect information leading to a final
confirmatory study for AI research.
1.3 SMART and Other Designs
In this chapter, I compare SMART and several RCT designs that share some common
features with SMART more or less. The similarities between SMART and these designs
sometimes cause confusions for clinical trialists who get to know SMART at the beginning.
By making these comparisons, I further demonstrate the unique features of SMART in
the family of RCT designs.
Crossover design is a repeated measurement RCT design such that individuals receive
varying treatment sequences across multiple stages (Brown, 1980). Operationally, the
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sequential feature makes SMART somewhat similar to the crossover design. However, the
motivation of SMART differs from that of the crossover design completely. A crossover
design is motivated to improve the efficiency and reduce the sample size of a study
aiming to compare non-adaptive interventions. But a SMART aims to compare adaptive
interventions. Also, the treatment assignment in a crossover study only depends on the
results of randomization at baseline. For example, in a crossover study comparing the
treatment effects of A versus B, every patient is assigned to receive either a sequence of
“A → B” or “B → A” at baseline. Once the treatment program initiates, every patient
follows the assigned treatment sequence to the end of the study unless he or she drops
out. In SMART, only the set of decision rules are pre-specified at baseline. It is unlikely
to know the treatment sequence actually received by a patient until the last decision
is made. The major pitfall of a crossover design is carryover effect such that the prior
treatment effect A (or B) may be confounded with the succeeding treatment effect B (or
A). To avoid the contamination of carryover effects, a crossover design typically inserts a
unique component called washout period between two treatment periods within a subject.
The key of setting up a washout period is to control the time long enough to diminish any
possible carryover effect. Nevertheless, a SMART aims to assess the effects of AIs, which
could possibly be a result of delay effects of early treatments. Therefore, synergistic
interactions between multi-stage treatments are of interest and thus a SMART design
typically does not consider to rule out carryover effect.
Adaptive design uses interim data of a study to modify some design aspects (e.g.,
randomization scheme) of a trial as it continues, without undermining the validity and
integrity of the study (Gallo et al., 2006). Comparing to SMART, adaptive design is
a broader concept that covers a family of RCT designs paralleled to SMART, includ-
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ing continual reassessment design (Garrett-Mayer, 2006), Seamless design (Maca et al.,
2006), enrichment design (Wang Hung and O’Neill, 2009), sample size recalculation design
(Proschan, 2009) and adaptive randomization design (Zhang and Rosenberger, 2012), all
sharing a common feature of having opportunities to modify one or several design aspects
based on the results of interim analysis (Coffey et al., 2012). Adaptive design is motivated
by improving the overall quality of care for trial participants in favor of the treatments
showing better efficacy or less toxicity during the early period of a trial and thus the
between-subject information is adapted. On the other hand, the treatment assignment
of a patient in SMART is adapted to the within-subject information, while the common
design elements (e.g., sample size, randomization scheme, etc.) are pre-specified to the
trial and will not be modified during the study. Cheung et al. (2015) proposed a de-
sign, Sequential Multiple Assignment Randomization Trial with Adaptive Randomization
(SMART-AR), which can improves the quality of patient care by adapting some design
parameters in a SMART framework. In SMART-AR, subjects received treatments based
on sequential randomization as in a classic SMART and the entire study was designed
into multiple stages so that some design parameters (e.g. randomization probabilities)
can be modified based on the interim analysis in the same clinical trial. The simulation
results indicated that overall quality of patient care can be improved by adjusting the
design parameters of adaptive randomization and the elites of SMART remain in the trial
with SMART-AR design. Further exploration of SMART-AR is open to researchers.
Factorial design decomposes the variation of primary outcome into the main effects
and possible interaction effects of one or several factors. Factorial design is a classic
experimental design that has been widely used not only in clinical trial research, but
also in a variety of areas, such as agriculture (Fisher, 1926), engineering (Giachetti et
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al., 2013), and marketing (Holland and Cravens, 1973). The experience about factorial
design can help to understand SMART design better. We can view SMART as a factorial
design under which time and treatment decisions play the essential roles (Chakraborty
et al., 2009). For example, in the DLBCL trial mentioned in Chapter 1.2, we can explain
the variation of primary outcome by 3 factors (stage-1 treatment, intermediate response
and stage-2 treatment) so as to make it a typical 3-way factorial design.
1.4 Motivation of Research
My dissertation research is motivated by developing statistical methods for SMART with
the goal of comparing multiple AIs. SMART provides a very flexible framework that
allows varying design structures according to the AIs of interest in study, featured by
the numbers of stages, treatment options and intermediate response categories. Figure
1.3 shows a modified design of the DLBCL trial in Figure 1.2, in which the intermediate
outcomes are separated into three categories and only PR patients undergo the second
randomization. Such a design leads to data that allow to compare 4 AIs, defined as
(1) CHOP followed by observation (for CR patients) or rituxamab (for PR patients) or
G-CSF (otherwise), (2) CHOP followed by observation (CR/PR) or G-CSF (otherwise),
(3) R-CHOP followed by observation (CR) or rituxamab (PR) or G-CSF (otherwise) and
(4) R-CHOP followed by observation (CR/PR) or G-CSF (otherwise). While Figure 1.4
gives another modified SMART design of the DLBCL trial that leads to data that allow
to compare up to 8 two-stage AIs similar to those defined in the DLBCL trial.
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Figure 1.3. Modified SMART design (A) of the DLBCL trial. CR: complete remission;
PR: partial remission; SD: stable disease; PROG: progression; REL: Relapse; CHOP:
cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHOP: rituximab plus

































Figure 1.4. Modified SMART design (B) of the DLBCL trial. CR: complete remission;
PR: partial remission; SD: stable disease; PROG: progression; REL: Relapse; CHOP:
cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHOP: rituximab plus



































It is interesting that the total number of AIs embedded in a SMART could increases
exponentially as the design structure gets more complicated, which typically reflects more
treatment stages, more treatment options or more intermediate response categories. For
example, when we compare the designs between Figure 1.2 versus Figure 1.4, as the
number of treatment options for patients who fail in stage-1 treatment increases from
one to two, the total number of AIs increases from 4 to 8. The sequential randomization
automatically generates SMART data of more than one pair of AIs. Unlike in a simple
RCT design aiming to compare non-adaptive treatments such that all the intervention
groups are independent, some AIs in a SMART are partially overlapped by certain treat-
ment sequences. For example, AI (1) and AI (2) described in the previous paragraph
are overlapped by two treatment sequences, which are “CHOP → CR → observation”
and “CHOP → stable disease/progression/relapse → G-CSF”. As results, the estimated
values of some AIs embedded in a SMART are correlated and the correlations vary by
design structures. Intuitively, patients who complete the treatment sequence of “CHOP
→ CR → G-CSF” in Figure 1.3 contribute data in estimating both AI (1) and AI (2) in
the previous paragraph. Therefore, the covariance between the estimated values of these
two AIs needs to be taken into consideration in the inference for comparing two AIs. A
well-developed method should be applicable to SMART with varying design structures.
The rest of my dissertation is organized as follows. In Chapter 2, I will propose a
Wald-type omnibus test, which can be applied as a gate-keeping test to select the best AI
embedded in SMART. This method is recommended in a early phase trial with the goal to
select one promising for further confirmatory study. I will show an application using a real
data set extracted from a smoking cessation trial. In Chapter 3, I will propose a method
to construct a set of simultaneous confidence intervals, called Multiple Comparison with
11
the Best Simultaneous Confidence Intervals, which can be used as a filter to identify the
inferior AIs and eliminate it from moving forward in a series of experimental studies. I will
show an application using the data collected from a depression management trial. I have
developed an R package, named SRT (Sequential Randomized Trial) for implementing
SMART design. This package contains most commonly used methods in SMART settings
and both the methods proposed in my dissertation have also been built in this package.
I will introduce this R package and illustrate the usage of this R package in Chapter 4.
In Chapter 5, I will report an exploratory study that illustrates using SMART design to
improve the efficiency comparing to a traditional randomized clinical trial in a depression
prevention study. This dissertation ends up with conclusion and some discussions about
future directions in Chapter 6.
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Chapter 2 A Gate-keeping Test for Selecting Adaptive Intervention under
General SMART Designs
2.1 Introduction
An adaptive intervention (AI) consists of a sequence of treatment decisions made based
on a patient’s historical clinical information, such as treatment history and responses
to previous treatments. AI has long been a common treatment strategy in the clinical
practice for cancer, mental disorders, and many other chronic conditions. Evaluation of
AIs in experimental settings, on the other hand, has been considered only recently in the
context of sequential multiple assignment randomized trial (SMART; Rush et al., 2004;
Thall et al., 2007). A SMART may be viewed as a clinical trial design that provides
data about a collection of randomly assigned AIs that may overlap in terms of treatment
decisions. In many situations, a SMART could facilitate the selection and the priori-
tization of interventions in a series of experimental studies that lead to a confirmatory
trial (Murphy, 2005). As such, a natural research objective of a SMART is to determine
whether or not an AI should be moved forward for further investigation. Specifically, in
this chapter, I consider a method related to the selection of AIs embedded in a SMART.
By virtue of randomization upon observing treatment history and tailoring response,
the value of each AI can be consistently estimated using G-computation under structural
nested models (Robins, 1986; Lavori et al., 2007) and inverse probability weighted esti-
mation under the marginal mean models (Murphy et al., 2001; Orellana, Rotnitzky, and
Robins, 2010). Thus, the best AI embedded in a SMART may be selected by comparing
the estimated values of all AIs embedded in the SMART. This approach entails multi-
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ple pairwise comparisons of AIs. As a main concern in a randomized clinical trial is to
protect against false positive finding (Hochberg and Tamhane, 1987), multiplicity adjust-
ments are necessary when numerous AIs are evaluated in a comparative fashion. While
Bonferroni method is a versatile approach that can be directly applied to the multiple
comparison problem in a SMART, it is also known to be conservative. Furthermore, such
a problem is magnified when we compare multiple AIs using SMART data. Because the
total number of pairwise comparisons needed to be adjusted in SMART sometimes in-
creases exponentially as the design structure gets more complicated. For example, Figure
1.4 is a modified of the DLBCL trial. Comparing to the original design shown in Figure
1.2, one more option has been added to the stage-2 treatment for patients who failed
to achieved PR/CR at Stage 1 in the modified SMART design. Consequently, the total
number of AIs increases from 4 to 8 so that the number of pairwise comparisons needed
to be adjusted by Bonferroni’s method increases from 6 to 28. As an alternative, one
could account for multiplicity by using a gate-keeping approach whereby the selection of
AI will be made only when the hypothesis of no difference among the AIs of interest is
rejected. Several omnibus tests have been proposed in the literatures; see, for example,
Orellana et al. (2010), Nahum-Shani et al. (2012), and Ogabagaber, Karp and Wahed
(2016). Using a gate-keeping approach, one can justify the total sample size of a SMART
formally with respect to the targeted type I error rate and the power of the omnibus
test. While most sample size formulae for SMARTs were derived for comparing two AIs
with or without overlap in treatment decisions (e.g., Murphy, 2005; Oetting et al., 2009),
powering a study based on an omnibus test is arguably more relevant than one based
on pairwise comparisons, because the former accounts for all embedded AIs. Indeed, in
many cases, it is practically challenging for a trialist to choose only one pair of AIs to
14
power a SMART due to lack of information. For example, for lymphoma patients who fail
in the front-line chemotherapy, there are many salvage regimens available that can form
multiple AIs. However, it is difficult to select a pair of AIs for sample size calculation
because these regimens are equally likely to be effective. In such situations, powering a
SMART based on an omnibus test is more reasonable than based on a pairwise compari-
son. Ogabagaber et al. (2016) recently gave an excellent review of sample size calculation
for SMARTs, and considered sample size determination for a Wald test based on inverse
probability weighted estimation under three specific SMART designs. In this Chapter, I
will proposed a gate-keeping approach using an omnibus Wald test based on maximum
likelihood estimation, and discuss the method of calculating sample size associated with
this test in Chapter 2.2.
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Figure 2.1. Design structure of smoking cessation trial
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While there is a wide applications of SMART, we will illustrate the proposed method
using data extracted from a smoking cessation randomized trial at the Center for Health
Communications Research (CHCR) at the University of Michigan (Strecher et al., 2008).
Figure 2.1 is the design structure of this trial. Briefly, in this trial, four options of
behavioral treatments defined by two 2-level factors were available for randomization at
the first treatment stage, and then two options at the second stage. The study aimed
to improve adult smoking quitting rate. The AIs embedded in this example are listed in
Tables 2.1 along with some numerical results of the analysis. Additional details are given
in Chapter 2.4.
Table 2.1. Multiple Comparison of adaptive interventions embedded in CHCR study.
The P values were obtained from pairwise tests comparing each AI with the observed
best (g = 1). Bonferroni’s adjustment would require P < 0.0004 to achieve an overall
significance at 5%.
Stage-1 Stage-2 Treatment for
AI (g) Treatment Non-response Response θˆg (sd) P-value
1 Low source/low depth control control 0.43 (0.10) -
2 Low source/low depth control treatment 0.42 (0.08) 0.913
3 Low source/low depth treatment control 0.31 (0.08) 0.057
4 Low source/low depth treatment treatment 0.30 (0.06) 0.194
5 Low source/high depth control control 0.42 (0.08) 0.962
6 Low source/high depth control treatment 0.27 (0.07) 0.191
7 Low source/high depth treatment control 0.35 (0.07) 0.525
8 Low source/high depth treatment treatment 0.20 (0.06) 0.044
9 High source/low depth control control 0.22 (0.08) 0.096
10 High source/low depth control treatment 0.32 (0.06) 0.363
11 High source/low depth treatment control 0.29 (0.08) 0.290
12 High source/low depth treatment treatment 0.40 (0.06) 0.787
13 High source/high depth control control 0.40 (0.08) 0.841
14 High source/high depth control treatment 0.37 (0.07) 0.630
15 High source/high depth treatment control 0.42 (0.07) 0.965
16 High source/high depth treatment treatment 0.39 (0.06) 0.741
sd: estimated asymptotic standard deviation of θˆg
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The rest of this chapter is organized as follows. Chapter 2.2 specifies setting, notation,
and model, introduces the proposed Wald test, and discusses sample size determination
based on the proposed test. Chapter 2.3 evaluates finite sample performance of the
proposed method using simulation. Chapter 2.4 shows an application using the real data
example of the smoking cessation trial. It ends with some discussion in Chapter 2.5.
2.2 An Omnibus Test for Comparing Multiple Adaptive Interventions
2.2.1 Setting, Notation and Model
For brevity in exposition, I consider SMART designs with the primary objective to com-
pare two-stage AIs, although the notation can be readily extended to any SMART design
with more than 2 stages. Suppose that there are I treatment options T1, . . . , TI at Stage
1, and under treatment Ti, there are Ji possible intermediate responses, denoted by
Ri1, . . . , RiJi for i = 1, . . . , I. Next suppose that for a subject who receives treatment Ti
at Stage 1 and has an intermediate response of Rij, there are Kij treatment options at
Stage 2, namely Sij1, . . . , SijKij , for i = 1, . . . , I; j = 1, . . . , Ji. The design structure of a
two-stage SMART is thus completely specified by the set of
{(Ti, Rij, Sijk) : i = 1, . . . , I; j = 1, . . . , Ji; k = 1, . . . , Kij}
and is depicted in Figure 2.1. Let Ul denote the treatment received at Stage 1, Xl
the intermediate response observed at the end of Stage 1, Vl the treatment received at
Stage 2, and Yl the final primary outcome observed at the end of Stage 2 for subject
l, where l = 1, . . . , n. For example, the primary outcome Yl is a binary indicator of
17
quitting smoking in the CHCR smoking cessation study. Let pii = Pr(Ul = Ti) be the
randomization probability of assigning Ti to subject l at Stage 1, and piijk = Pr(Vl =
Sijk|Ul = Ti, Xl = Rij) be the randomization probability of assigning treatment Sijk to
patient l given the clinical history of stage-1 treatment and response (Ul = Ti, Xl = Rij).
The randomization scheme of a two-stage SMART can be completely specified by
{(pii, piijk) : i = 1, . . . , I; j = 1, . . . , Ji; k = 1, . . . , Kij},
and is depicted in Figure 2.2. Here I subtracted the subject indicator, l, for simplicity.






























Stage-1 Treatment        
Intermediate outcome        





Figure 2.2. General scheme of two-stage SMART design
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The data obtained from the lth patient who has completed a SMART can be summa-
rized as (Ul, Xl, Vl, Yl) for l = 1, . . . , n, and are assumed to be independent and identically
with the following distributions:
Pr(Ul = Ti) = pii, i = 1, . . . , I,
Pr(Xl = Rij|Ul = Ti) = pij, j = 1, . . . , Ji, i = 1, . . . , I,
Pr(Vl = Sijk|Ul = Ti, Xl = Rij) = piijk, k = 1, . . . , Kij, j = 1, . . . , Ji, i = 1, . . . , I,





where pij is the probability of observing intermediate response Rij given stage-1 treatment
Ti, φijk is the parameter of interest, and τijk, possibly a vector, is the nuisance parameter.




satisfies the regularity conditions specified in Theorem 5.39 in
van der Varrt (1998) which guarantee the asymptotic efficiency of the maximum likelihood
estimator (MLE) of (φijk, τijk). For example, data arising from a distribution belonging
to the exponential family will satisfy the conditions. The stage-specific randomization
probabilities pii and piijk are known by design in SMART.
An two-stage AI, under which a patient receives treatment Ti at Stage 1 and will
receive treatment Sijkij at Stage 2 if an intermediate response of Rij is observed, can be
denoted by
di;ki1,...,kiJi = (Ti;Si1ki1 , . . . , SiJikiJi ),
where i = 1, . . . , I and kij = 1, . . . , Kiji for ji = 1, . . . , Ji. Note that (ki1, . . . , kiJi) is an
element in the product set
∏Ji
j=1{1, . . . , Kij}. Under the general SMART design given in
Figure 2.2, the total number of AIs with Ti at Stage 1 is Gi =
∏Ji
j=1Kij, and thus the
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total number of AIs embedded in a SMART is G =
∑I
i=1Gi.
Let θi;ki1,...,kiJi be the value of an two-stage AI embedded in a general SMART design
described in previous paragraph. Note that under an AI, di;ki1,...,kiJi , there are Ji possible
treatment sequences, (Ti, Rij, Sijk), which a patient can possibly follow. Therefore, the
AI value can be defined as the expected outcome Y across all the possible treatment





An AI di;ki1,...,kiJi is said to be the best among all the AIs embedded in a SMART if it












Note that there could be more than one best AI embedded in a SMART design.
2.2.2 Maximum Likelihood Estimation
In this section, I consider the maximum likelihood estimator (MLE) for an AI value
θi;ki1,...,kiJi and examine its asymptotic distribution. The MLE of an AI is obtained by
plugging in the MLEs of pij’s and φijk’s, which are obtained by maximizing the joint
distribution of
{
(Ul, Xl, Vl, Yl); l = 1, . . . , n
}
.
Specifically, to obtain a MLE, I first derive the log-likelihood function based on the
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joint probability distribution of
{
(Ul, Xl, Vl, Yl); l = 1, . . . , n
}
as



















I(Ul = Ti, Xl = Rij, Vl = Sijk) log pij + constant.






















I(Ul = Ti, Xl = Rij, Vl = Sijk)








I(Ul = Ti, Xl = Rij, Vl = Sijk)
∂ log f(yl|φijk, τijk)
∂τijk
,
where i = 1, . . . , I, j = 1, . . . , Ji, and k = 1, . . . , Kij.










k=1 I(Ul = Ti, Xl = Rij′ , Vl = Sij′k)
,
and the MLEs for φijk and τijk are the ones based on the subset of Yl’s such that Ul =
Ti, Xl = Rij, Vl = Sijk, and are denoted as φˆijk and τˆijk, respectively. For example, in
a SMART that we are interested in the continuous primary outcome that is assumed to
follow a normal distribution,
Yl|(Ul = Ti, Xl = Rij, Vl = Sijk) ∼ N(φijk, σ2ijk),
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where the mean, φijk, is the parameter of interest and the variance, σ
2
ijk, is the nuisance
parameter. I can get the MLE for φijk and σ
2
ijk by taking the sample average and variance
of those patients with the treatment history of (Ti, Rij, Sijk). Note that in general there
is no closed form expression for φˆijk or τˆijk.

















so that pˆi, φˆij and φˆi their MLEs, respectively.
Let θi be the vector of values of all the AIs starting with Ti at Stage 1, which are
denoted by θi,ki1,...,kiJi and arranged in the lexicographical order of (ki1, . . . , kiJi). Also,
let Gi =
∏Ji
j=1Kij and mi =
∑Ji
j=1Kij. Here θi can be expressed in two forms as
θi = AiΛi(pi)φi = AiΓi(φi)pi , (1)
where Ai is an Gi ×mi matrix defined as
Ai =
(




⊗ denotes the Kronecker product, and Λi(pi) is an mi ×mi block diagonal matrix
Λi(pi) = bdiag
{




and Γi(φ) is an Gi × Ji block diagonal matrix
Γi(φi) = bdiag
{
φij; j = 1, . . . , Ji
}
,
where “bdiag{·}” denotes block diagonal matrix.
The two expressions of the MLE of θi in (1) can be respectively expressed as


















σ2(φijk, τ ijk); k = 1, . . . , Kij
}
,
and σ2(φijk, τijk) =
(
ıφijkφijk − ıTφijkτijk · ı−1τijkτijk · ıφijkτijk
)−1
,
where  ıφijkφijk ıTφijkτijk
ıφijkτijk ıτijkτijk

is the block Fisher’s information matrix of distribution f(y|φijk, τijk).
Theorem 1 Let Θ = (θT1 , . . . ,θ
T
I )
T . Under regularity conditions given in Theorem 5.39
in van der Vaart (1998), as n→∞,
√
n(Θˆ−Θ) d−→ N(0, Σ), (3)
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Kij − Ji + 1 = mi − Ji + 1. (4)
Theorem 1 shows that the MLE θˆi is asymptotically normal, and that the asymptotic
covariance matrix Σθi is not of full rank Gi when Ji ≥ 2. This is the fundamental
distributional result on which all the proposed techniques are built. The proof of Theorem
1 is given in the Appendix 1.
2.2.3 Wald Test and Sample Size Determination
I propose in this section a Wald-type omnibus test and discuss the sample size determi-
nation based on the proposed test. For ease of exposition, I use θg to denote the gth
component of Θ, where g = 1, . . . , G, G is the total number of AIs and Θ is the vector of
all the AI values, θi;ki1,...,kiJi , embedded in a SMART, arranged in a lexicographical order
of (i; ki1, · · · , kiJi). As an initial step of a gate-keep approach to identify the best AI, an
omnibus test of equality is considered with the following hypotheses:
H0 : θ1 = · · · = θG versus H1: θg’s are not all equal for g = 1, . . . , G. (5)
Let C = (1G−1| − IG−1) be a (G− 1)×G contrast matrix such that the first column
is a (G− 1) vector of 1’s and the j-th column is a (G− 1) vector whose (j − 1)-th entry
is -1 and other entries are zeros, where 2 ≤ j ≤ G. Let Σ be the covariance matrix of Θˆ
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defined in Theorem 1, and Σˆ is the plug-in estimator of Σ by replacing pij, θijk, τijk with
their MLEs pˆij, θˆijk, τˆijk, respectively. Then a Wald-type test statistic can be written as
Q = n(CΘˆ)T (CΣˆCT )−(CΘˆ), (6)
where M− denotes the generalized inverse of a square matrix M .
Theorem 2 Suppose all regularity conditions given in Theorem 5.39 in van der Vaart















Ji + I − 1. (7)




T (CΣCT )−(CΘn) = λ∗ > 0, (8)
Q
d−→ χ2ν(λ∗), a noncentral chi-squared distribution of ν degrees of freedom with noncen-
trality parameter λ∗.
As a consequence to Theorem 2, an asymptotic level α test rejects H0 in (5) if the
test statistic Q > χ2ν,α, where χ
2
ν,αthe (1 − α)th percentile of the central chi-squared
distribution with ν degrees of freedom. Note that in a special case that rank(Σθi) = 1, it
reduces to the regular Wald test for comparing non-adaptive intervention sequences.
Theorem 2 also provides a basis for sample size determination, which may proceed
prescriptively as follows:
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Step 1: For a given design structure of SMART {Ti, Rij, Sijk}, where i = 1, . . . , I; j =
1, . . . , Ji; k = 1, . . . , Kij, calculate the degrees of freedom ν according to (7).
Step 2: For a prespecified type I error rate α and a targeted power of 1−β, determine the
noncentrality parameter λ∗ required under the alternative hypothesis by solving
χ2ν,1−β(λ
∗) = χ2ν,α(0), where χ
2
ν,α(λ
∗) denotes the (1−α)th percentile of a noncen-
tral chi-squared distribution with degrees of freedom ν and λ∗ is the noncentrality
parameter.
Step 3: For given design parameters {pii, piijk}, assumed intermediate response probabil-
ities {pij} and primary outcome parameter values {φijk, τijk} for the outcome
distribution f , calculate the targeted AI values Θ∗ and its covariance Σ∗, so that















Table 2.2 gives the values of noncentrality parameter λ∗ under some commonly used
targeted type I and II errors, (α, β), in clinical trials. Generally, smaller error rates and
larger degrees of freedom, which reflects the numbers of treatment options and response
categories, require a larger λ∗, and hence a larger sample size per Step 4 above.
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Table 2.2. Noncentrality parameter (λ∗) of chi-squared distribution with ν degrees of
freedom. α is type I error, β is type II error.
(α, β)
Degrees of freedom (ν) (0.01, 0.10) (0.01, 0.20) (0.05, 0.10) (0.05, 0.20) (0.10, 0.10) (0.10, 0.20)
2 17.42 13.88 12.65 9.63 10.45 7.71
3 19.24 15.45 14.17 10.90 11.79 8.80
4 20.73 16.75 15.41 11.94 12.88 9.68
5 22.02 17.87 16.47 12.83 13.81 10.44
6 23.18 18.87 17.42 13.62 14.65 11.13
7 24.23 19.78 18.28 14.35 15.41 11.75
8 25.20 20.63 19.08 15.02 16.11 12.32
9 26.12 21.42 19.81 15.65 16.76 12.86
10 26.98 22.17 20.53 16.24 17.38 13.36
11 27.79 22.88 21.20 16.80 17.96 13.84
12 28.57 23.56 21.83 17.34 18.52 14.30
13 29.31 24.21 22.44 17.85 19.05 14.74
14 30.03 24.83 23.02 18.34 19.56 15.16
15 30.71 25.43 23.58 18.81 20.06 15.56
16 31.38 26.01 24.13 19.27 20.53 15.95
17 32.02 26.57 24.65 19.71 20.99 16.33
18 32.65 27.11 25.16 20.14 21.43 16.69
19 33.25 27.64 25.65 20.56 21.87 17.05
20 33.84 28.16 26.13 20.96 22.29 17.39
2.3 Finite Sample Performances
Having established the asymptotic properties of the Wald test in the previous section, I
evaluate its performances in finite sample size settings using simulation in this section.
In addition, the test is applied as a gate-keeping method: if the test fails to reject H0
in (5), I will stop further comparison and conclude that there is no sufficient evidence
to support any AI being better than the others. However, if H0 is rejected, I proceed
to select the AI with the highest estimated value and recommend it for further clinical
evaluation.
The properties of the test and the selection procedure are examined under a variety
of SMART designs (Chapter 2.3.1) and outcome scenarios (Chapter 2.3.2).
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2.3.1 SMART Designs
Figure 2.3 gives the structures of three two-stage SMART designs considered in simu-
lation. The first design structure (DS1) mimics the situation in which there are two
treatment options at each decision making point, that is, Ti, Sijk ∈ {0, 1}, and binary
intermediate outcome, that is, Rij ∈ {0, 1} for i, j, k = 1, 2. As a result, there are eight
possible AIs embedded in DS1. Under DS2 and DS3, there are also two treatment op-
tions at Stage 1. However, randomization at Stage 2 may be restricted for patients with










































Design Structure 3 (DS3) 
Figure 2.3. Design structures considered in the simulation.
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Under each design structure, a SMART design is completely specified by the set
{pii, piijk} of randomization probabilities defined in Chapter 2.2.1. I considered three sets
of randomization probabilities for each design structure in Figure 2.2. First, I considered
balanced randomization (BR) scheme, that is, Pr(U = 1) = 0.5 and Pr(V = 1|U,X) =
0.5 whenever there is an option of randomization at Stage 2. Second, I considered an
unbalanced randomization (UBR) scheme, where Pr(U = 1) = 0.7 and Pr(V = 1|U,X) =
0.7 whenever there is an option of stage-2 randomization. Third, I considered Pr(U =
1) = 0.5 at Stage 1, Pr(V = U |U,X = 0) = 0.3 and Pr(V = U |U,X = 1) = 0.7 at Stage
2, whenever there is an option of second stage randomization. Under this scheme, Stage
2 implements a randomized play-the-winner (RPTW) rule for the situations where the
first and the second stage treatment options are identical.
In summary, the three design structures (DS1, DS2, DS3) and the three randomiza-
tion schemes (BR, UBR, RPTW) yielded 9 SMART designs under which the multiple
comparison procedures were evaluated in the simulation.
2.3.2 Outcome Scenarios in Simulation
In a simulated SMART trial with a total sample size of n, the treatment assignment
(Ul, Vl) of the lth patient was generated according to one of the randomization schemes
in Chapter 2.3.1. The intermediate response rate was set as Pr(Xl = 1|Ul = Ti) = 1/3
for Ti ∈ {0, 1}. Given the lth subject’s treatment history and intermediate response
(Ti, Rij, Sijk), his or her outcome Yl was randomly generated from a normal distribution
with mean φijk = φ(Ti, Rij, Sijk) and variance σ
2 = 100, where the conditional mean φijk
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was specified by
φ(Ti, Rij , Sijk) = β0+β1Ti+β2Rij+β3Sijk+β4TiRij+β5TiSijk+β6RijSijk+β7TiRijSijk (10)
for Ti, Rij, Sijk ∈ {0, 1}. The parameter β = (β0, β1, β2, β3, β4, β5, β6, β7)T was chosen so
that the true values θi;ki1,...,kiJi ’s would follow the patterns displayed in Figure 2.4. Under
Value Pattern 1 (VP1; top panel), AIs with the same stage-1 treatment had the same
values; under VP2, the values of the AIs were uniformly higher if their stage-1 treatment
was U = 1; under VP3 (bottom panel), the best AI had stage-1 treatment U = 1 while the
second best had stage-1 treatment U = 0, and so on and so forth, following an alternating
pattern. The value of β was chosen so that the effect size was ∆ = 0.05 or 0.10. For
example, under VP1, β0 = β2 = · · · = β7 = 0 and β1 = 4.48 and 6.33 yielded ∆ = 0.05
and 0.10, respectively. Details about how to choose β for each pattern are provided in
Appendix 2. All sets of β values used in the simulation scenarios are given in Table 2.3.
Table 2.3. Values of (β0, β1, β2, β3, β4, β5, β6, β7) used in simulations.
(β0, β1, β2, β3, β4, β5, β6, β7)
Design Structure Value Pattern ∆ = 0.05 ∆ = 0.10
DS1 VP1 (0, 4.48, 0, 0, 0, 0, 0, 0) (0, 6.33, 0, 0, 0, 0, 0, 0)
DS1 VP2 (0, 3.63, 0, 2.62, 0, 0, 0, 0) (0, 5.13, 0, 3.70, 0, 0, 0, 0)
DS1 VP3 (0, 1.86, 0, 3.73, -9.32, 1.86, -0.93, 0) (0, 2.64, 0, 5.82, -13.20, 2.64, -1.32, 0)
DS2 VP1 (0, 4.48, 0, 0, 0, 0, 0, 0) (0, 6.33, 0, 0, 0, 0, 0, 0)
DS2 VP2 (0, 0, 0, 2.88, 12, 0, 0, 0) (0, 0, 0, 4.13, 17.70, 0, 0, 0)
DS2 VP3 (0, -1.21, 0, 4.82, 4.82, 1.21, 0, 0) (0, -1.72, 0, 6.87, 6.87, 1.72, 0, 0)
DS3 VP1 (0, 4.48, 0, 0, 0, 0, 0, 0) (0, 6.33, 0, 0, 0, 0, 0, 0)
DS3 VP2 (0, 1.29, 0, 3.88, 0, 0, 0, 0) (0, 1.82, 0, 5.47, 0, 0, 0, 0)
DS3 VP3 (0, 0, 0, -4.46, 0, 6.69, 0, 0) (0, 0, 0, -6.36, 0, 9.54, 0, 0)
Details of design structures (DS) and value patterns (VP) are given in Figures 2.2 and 2.3
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Figure 2.4. Value patterns of AIs considered in the simulation.
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2.3.3 Gate-Keeping Approach for AI Selection
Here I evaluate a multiple comparison procedure applies the likelihood-based Wald test
proposed in Chapter 2.2.3 as a gate-keeping method: if the test fails to reject H0 in (5), I
will stop further comparison and conclude that there is no sufficient evidence to support
any AI being better than the others. If H0 is rejected, I will proceed to select the AI with
the highest estimated value and recommend it for further clinical investigation.
Table 2.4 gives the actual type I error rates of the proposed Wald test at 5% nomi-
nal significance level, based on 5,000 simulation replicates under the 9 SMART designs
described in Chapter 2.3.1 with a total sample size of n = 200 in outcomes scenarios
generated with β = (0, 0, 0, 0, 0, 0, 0, 0) in (10). Overall, the actual type I error rates
are very close to the nominal level in all the 9 designs. For comparison purposes, I also
considered pairwise testing procedures comparing the AIs, with or without multiplicity
adjustment. The procedure without multiplicity adjustment would reject the null H0 in
(5) if any pairwise test had a P-value less than 0.05. As expected, this procedure led to
inflated type I error rates, especially under DS1 where there were many comparisons (i.e.,
28 in total). For the pairwise testing procedure with multiplicity adjustment, we used
the Bonferroni’s method and adjusted significance level for each individual test accord-
ing to the number of comparisons under each DS (i.e., 28, 6, and 3 for DS1, DS2, and
DS3, respectively). Specifically, we would reject the H0 in (5) if any pairwise test had
a P-value less than 0.0018, 0.0083, and 0.0167 under DS1, DS2, and DS3, respectively.
Table 2.4 shows that the Bonferroni’s correction was conservative, especially under DS1
where many comparisons were accounted for.
32
Table 2.4. Type I error rate of the proposed Wald test and the two pairwise test proce-
dures at 5% ominal significance under H0 in (5) and a total sample size of n = 200.




DS1 BR 0.051 0.355 0.022
UBR 0.048 0.293 0.015
RPTW 0.049 0.336 0.020
DS2 BR 0.051 0.196 0.043
UBR 0.050 0.171 0.035
RPTW 0.050 0.188 0.039
DS3 BR 0.051 0.114 0.040
UBR 0.048 0.112 0.039
RPTW 0.053 0.115 0.042
Table 2.5 compares the power of the Wald test and those of pairwise tests with Bon-
ferroni’s corrections for the outcome scenarios given in Table 2.3 under different SMART
designs. Overall, the Wald test was more powerful than the Bonferroni’s adjusted pair-
wise tests in all scenarios and designs considered. For each given effect size (∆), the
power of the pairwise testing procedure had a sharp drop under DS1 when compared
with the other design structures, likely due to the needs to adjust for many comparisons.
In contrast, while the Wald test also had lower powers under DS1 than under DS2 and
DS3, the drop was much less substantial. This demonstrated that an omnibus test was
advantageous over a pairwise comparison procedure because the former attenuated the
impact of a large number of AIs on the power of a SMART study. In addition, I calculated
the theoretical power of the Wald test (cf. Theorem 2) and noted that the asymptotic
approximation was accurate when n = 200.
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Table 2.5. Power of the proposed Wald test and the pairwise tests with Bonferroni’s
adjustment at 5% overall significant under scenarios given in Table 4 and a total sam-
ple size of n = 200.



















DS1 VP1 BR 0.679 0.672 0.582 0.953 0.951 0.906
UBR 0.590 0.581 0.405 0.907 0.908 0.753
RPTW 0.679 0.681 0.478 0.953 0.948 0.847
DS1 VP2 BR 0.679 0.672 0.597 0.952 0.943 0.919
UBR 0.589 0.573 0.415 0.905 0.908 0.805
RPTW 0.579 0.570 0.425 0.899 0.892 0.803
DS1 VP3 BR 0.679 0.673 0.470 0.953 0.946 0.833
UBR 0.669 0.662 0.372 0.949 0.945 0.753
RPTW 0.620 0.612 0.378 0.925 0.918 0.755
DS2 VP1 BR 0.763 0.761 0.729 0.975 0.977 0.968
UBR 0.680 0.679 0.577 0.946 0.941 0.888
RPTW 0.763 0.760 0.677 0.975 0.976 0.944
DS2 VP2 BR 0.763 0.759 0.747 0.975 0.974 0.973
UBR 0.696 0.691 0.561 0.959 0.958 0.906
RPTW 0.592 0.589 0.559 0.898 0.900 0.882
DS2 VP3 BR 0.763 0.758 0.648 0.975 0.976 0.935
UBR 0.726 0.728 0.526 0.964 0.966 0.849
RPTW 0.673 0.683 0.553 0.941 0.947 0.852
DS3 VP1 BR 0.817 0.808 0.756 0.985 0.985 0.979
UBR 0.741 0.734 0.649 0.965 0.964 0.928
RPTW 0.817 0.822 0.769 0.985 0.984 0.970
DS3 VP2 BR 0.817 0.810 0.796 0.985 0.983 0.981
UBR 0.789 0.781 0.727 0.979 0.977 0.960
RPTW 0.703 0.701 0.668 0.950 0.946 0.936
DS3 VP3 BR 0.817 0.818 0.802 0.985 0.984 0.981
UBR 0.561 0.576 0.532 0.867 0.868 0.837
RPTW 0.878 0.877 0.850 0.995 0.996 0.992
theo: theoretical power; emp: empirical power.
Table 2.6 compares the proposed Wald test based on MLE and the Wald test based on
inverse probability weighted estimators (IPWE) described in Ogabagaber et al. (2016). I
extracted the scenarios and results of the IPWE Wald test from Table I in Ogabagaber et
al. (2016), calculated the sample size required by our proposed test (Chapter 2.2.3), and
evaluated the power of our test using simulation. The proposed test generally required a
smaller sample size while achieving comparable power with IPWE test. This is because
my reference distribution, derived based on asymptotic theory of the MLEs, accounts for
the fact that the asymptotic covariance matrix Σ in (3) is generally less than full rank.
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Table 2.6. Comparison of the proposed Wald test and the IPWE Wald test.
Required sample size Empirical power
Pr(X = 1|U = 0) Pr(X = 1|U = 1) Pr(V = 1|X = 1) Nominal Power IPWE Proposed IPWE Proposed
0.5 0.5 0.5 0.80 70 63 0.84 0.84
0.5 0.5 0.7 0.80 79 70 0.85 0.83
0.5 0.5 0.5 0.90 89 80 0.92 0.95
0.5 0.5 0.8 0.90 120 107 0.92 0.95
0.5 0.2 0.5 0.80 83 75 0.83 0.82
0.5 0.2 0.7 0.80 92 81 0.83 0.84
0.5 0.2 0.5 0.90 106 96 0.90 0.94
0.5 0.2 0.8 0.90 134 117 0.92 0.94
0.7 0.5 0.5 0.80 62 56 0.85 0.84
0.7 0.5 0.7 0.80 71 63 0.85 0.85
0.7 0.5 0.5 0.90 79 71 0.92 0.95
0.7 0.5 0.7 0.90 91 81 0.92 0.94
0.2 0.7 0.5 0.80 72 65 0.84 0.83
0.2 0.7 0.7 0.80 82 70 0.84 0.84
0.2 0.7 0.5 0.90 92 83 0.91 0.94
0.2 0.7 0.7 0.90 104 90 0.92 0.92
Table 2.7 gives the selection properties of the gate-keeping method with the proposed
Wald test under balanced randomization. As expected, the actual type I error rate, being
close to the nominal level of 5%, was equally distributed among all the AIs. Also, AIs
with higher true values were selected more often, and the selection accuracy improved
as the effect size ∆ became larger. Under VP1 where an AI had either a value of 0 or
a positive value, the probability of selecting an AI with a value of 0 was negligible. It
indicates that wrong selection by the gate-keeping approach after rejecting H0 is rare.
35
Table 2.7. The distribution of selected AI by the gate-keeping method after the Wald
test (at 5% level) under balanced randomization and a total sample size of n = 200.
∆ = 0.00 ∆ = 0.05 ∆ = 0.10
DS1-Null DS1-VP1 DS1-VP2 DS1-VP3 DS1-VP1 DS1-VP2 DS1-VP3
AI Value Prob. Value Prob. Value Prob. Value Prob. Value Prob. Value Prob. Value Prob.
(0;0,0) 0.00 0.006 0.00 0.000 0.00 0.000 0.00 0.001 0.00 0.000 0.00 0.000 0.00 0.000
(0;0,1) 0.00 0.006 0.00 0.000 0.87 0.000 0.93 0.005 0.00 0.000 1.23 0.000 1.32 0.001
(0;1,0) 0.00 0.006 0.00 0.000 1.75 0.001 2.49 0.045 0.00 0.000 2.47 0.000 3.52 0.033
(0;1,1) 0.00 0.006 0.00 0.000 2.62 0.007 3.42 0.209 0.00 0.000 3.70 0.001 4.84 0.300
(1;0,0) 0.00 0.006 4.48 0.169 3.63 0.018 -1.24 0.000 6.33 0.241 5.13 0.009 -1.76 0.000
(1;0,1) 0.00 0.006 4.48 0.168 4.50 0.068 0.31 0.000 6.33 0.251 6.36 0.053 0.44 0.000
(1;1,0) 0.00 0.006 4.48 0.166 5.38 0.119 2.48 0.027 6.33 0.231 7.60 0.120 3.52 0.014
(1;1,1) 0.00 0.006 4.48 0.167 6.25 0.458 4.04 0.385 6.33 0.228 8.83 0.759 5.72 0.598
∆ = 0.00 ∆ = 0.05 ∆ = 0.10
DS2-Null DS2-VP1 DS2-VP2 DS2-VP3 DS2-VP1 DS2-VP2 DS2-VP3
AI Value Prob. Value Prob. Value Prob. Value Prob. Value Prob. Value Prob. Value Prob.
(0;0,1) 0.00 0.012 0.00 0.000 0.00 0.000 0.00 0.000 0.00 0.000 0.00 0.000 0.00 0.000
(0;1,1) 0.00 0.012 0.00 0.000 1.92 0.003 3.21 0.181 0.00 0.000 2.77 0.000 4.59 0.170
(1;0,1) 0.00 0.013 4.48 0.380 4.00 0.076 0.40 0.000 6.33 0.488 5.90 0.042 0.57 0.000
(1;1,1) 0.00 0.013 4.48 0.381 5.92 0.678 4.42 0.576 6.33 0.489 8.67 0.932 6.31 0.806
∆ = 0.00 ∆ = 0.05 ∆ = 0.10
DS3-Null DS3-VP1 DS3-VP2 DS3-VP3 DS3-VP1 DS3-VP2 DS3-VP3
AI Value Prob. Value Prob. Value Prob. Value Prob. Value Prob. Value Prob. Value Prob.
(0;0,1) 0.00 0.0016 0.00 0.000 0.00 0.000 0.00 0.057 0.00 0.000 0.00 0.000 0.00 0.023
(0;1,1) 0.00 0.0016 0.00 0.001 2.59 0.034 -2.96 0.000 0.00 0.000 3.65 0.012 -4.24 0.000
(1;1,1) 0.00 0.0019 4.48 0.807 5.17 0.776 2.22 0.761 6.33 0.985 7.30 0.972 3.18 0.962
2.4 Application: Selecting the Best Web Design for Smoking Cessation
To demonstrate the use of proposed Wald test in a real data set, we show the application
using a data set from a two-stage web-based smoking cessation study conducted by Center
for Health Communications Research (CHCR) at University of Michigan (Strecher et al.,
2008). The first stage randomly directed subjects to 4 types of website with different
designs defined by two two-level behavioral factors, which are personalization of the
source materials (high source vs. low source) and the depth of success story narration
(high depth vs. low depth). The goal of the first stage was to help smokers to quit in a
6-month window.
• Personalization of source. Highly personalized source version website included a
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photograph of, and supportive text from, the smoking-cessation team of the HMO,
with friendly words like “we” and “our team”. Also, it ended the webpage with
a signature from the team. While low-personalized version only included a photo-
graph with the build of HMO institution and used impersonal terms, such as “this
organization”, with no signature.
• Depth of success story. Patients were directed to a webpage with a hypothetic
story about an individual who successfully quit smoking. A high-depth story re-
ferred to a success story tailored to a subject’s name, gender, age, ethnicity, martial
status, and a series of detailed information. While low-depth stories were only tai-
lored to the subject’s name and gender.
After the intermediate evaluation at 6 months after baseline, consenting patients in
the study were further randomized to the second stage between a website that included
in-depth materials (treatment) and one that contained only a brief message (control),
and were followed for another 6 months.
• Treatment website. Treatment websites included links to access the materials
selected from 8 original Forever Free relapse prevention booklets (Brandon et al.
2012). subjects logged in treatment websites received a welcome page that encour-
aged them to read any of the 8 web booklets that they felt important in helping in
their cessation efforts.
• Control website. Control websites only contained a brief message about the
subject’s current smoking status.
At the end of the second stage, the final smoking status was defined by a 7-day point
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prevalence abstinence and dichotomized as success versus failure [8]. Thus, the AI value
in our analysis was the probability of quitting smoke successfully in 12 months.
There were 16 AIs in total defined in this two-stage SMART (cf. Table 2.1). The
MLEs of all the AI values Θˆ were calculated using the study data in 282 patients and
listed in Table 2.1. The AI with Web-design combining ”Low source” and ”low depth” at
Stage 1 following by a website only contained a brief message about the patient’s current
smoking status (control) at Stage 2 has the highest estimated value (θ1 = 0.43). The
proposed Wald test was applied and the test statistics was obtained as Q = 19.14. As
the null distribution of the Wald test is chi-squared with 11 degrees of freedom according
to Theorem 2, I obtained P = 0.059. Hence, the procedure failed to reject null (5) at 5%
significance, and might not proceed to select an intervention. I note that the study was not
originally powered for this specific inferential purpose, but rather was analyzed separately
by stages (Strecher et al. 2008; Chakraborty, Strecher and Murphy, 2010). Having said
that, the omnibus test was quite close to reach significance at 5%. I also compared
the AI’s in pairwise fashion. The test results against the observed best AI (g = 1) are
reported in the last column of Table 2.1: Although there was one comparison had a P
value less than 0.05 (e.g. the AI with g = 8 and P = 0.044), multiplicity adjustment
would require a P value less then 0.0004 according to the Bonferroni’s method.
2.5 Discussion
I have proposed in this chapter a Wald test that can be applied as a gate-keeping test
for AI selection in a SMART. Also, I studied the selection properties of a gate-keeping
approach based on the proposed Wald test under SMART with varying design structures,
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randomization scheme and outcome scenario. As a results of the selection paradigm,
one can substantially reduce the sample size of a SMART by powering the study based
on a gate-keeping test, and thus improving feasibility of doing a SMART is promising.
Simulation study shows that the power of the proposed Wald test is affected by the
number of embedded AIs to a lesser extent than pairwise comparison with multiplicity
adjustments. As the “curse of dimensionality” is a major concern in evaluating AIs
embedded in a SMART, especially if we consider more than two stages and multiple
response categories, performing such an omnibus test as a gate-keeping test is a reasonable
approach on ground of feasibility.
From a practical viewpoint, the proposed test facilitates clear clinical decisions at the
end of a trial. In this article, I consider an approach whereby an AI is selected upon
rejecting the null of no difference. I note that the goal of a selection trial is not to select
the best intervention with high probability, but rather select an intervention that is not
“bad”: The two objectives coincide in scenarios where no AI falls in the indifference
zone (cf. VP1); see also the examples in Bechhofer, Santner, and Goldsman (1995) and
Cheung (2007). The proposed Wald test can be coupled with other clinical decision rules
such as identifying inferior interventions, as long as these rules are pre-specified. As a
case in point, the re-analysis of smoking cessation (cf. Table 2.1) shows that several AIs
(g = 2, 5, and 15) had estimated values close to the observed best (g = 1), whereas
some were clearly inferior to these promising AIs (g = 8). Retrospectively, it might
be appropriate to perform a unadjusted pairwise tests between the observed inferior AI
with the observed best AI, when the null hypothesis of the gate-keeping test in (5) was
rejected, and thus identify where the difference lied; e.g., the AI with g = 8 would have
been declared inferior according to this procedure. This multiple comparison procedure
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protect against false positive finding using the proposed Wald test in a similar manner
to Fisher’s least significant difference approach using ANOVA (Meier, 2006).
40
Chapter 3 Multiple Comparison with the Best Simultaneous Confidence In-
tervals to Identify Inferior Adaptive Interventions
3.1 Introduction
I introduced in previous chapter a Wald test built on Maximum likelihood estimator
(MLE) of adaptive intervention (AI). The proposed test can be applied as a gate-keeping
test for selecting the best intervention in SMART. In an early phase trial with the ob-
jective to select one promising or several near-best AIs, the gate-keeping test can help
to protect against the inflation of type I error rate due to an exhaustive search. In this
chapter, I view the multiple comparison problem from a different angle and propose a new
method to address it. Unlike the gate-keeping test that aims to select the best adaptive
intervention in SMART and move it forward to the final confirmatory trial, the method
proposed in this chapter help to identify the inferior AIs efficiently and then eliminate
the inferior AIs from moving to next phase investigation.
Specifically, I developed a method to build simultaneous confidence intervals, in which
I adopted the concept of Multiple Comparisons with the Best (MCB) simultaneous confi-
dence intervals proposed in Hsu (1984). The MCB concept was derived from the ranking
and selection literatures which lends itself to the problem of subset selection in Hsu (1981).
The idea is that each intervention is compared to the truly best intervention, which is
assumed to be unknown, using confidence interval; any intervention with a confidence
interval excluding zero will be identified as inferior to the truely best. The concept of
MCB is appealing for a SMART where a clinical trialist expects some AIs would have
lower values comparing to the majority of the AIs and thus the goal of the study is to
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effectively identify the inferior AIs. While the original method for constructing MCB
confidence intervals has been well studied for non-adaptive interventions comparisons, it
was built on traditional randomized clinical trial design that randomly assigns patients to
several independent groups for comparing non-adaptive interventions. The methods was
derived based on known correlation structures. Considering the correlations structure
between the estimates of adaptive intervention values derived based on SMART data is
typically unknown priori, the original method can not be directly applied to SMART
settings. In this chapter, a stepwise algorithm that extends the idea in Edwards and Hsu
(1983) to construct MCB intervals for AIs embedded in a SMART setting is proposed.
The method proposed in this chapter is motivated by a clinical examples that extracts
data from the CODIACS (Comparison of Depression Intervention after Acute Coronary
Syndromes) trial, which provides data that allow to evaluate up to eight adaptive inter-
ventions of depression management for patients who had surgeries after acute coronary
syndrome (ACS) [11]. Each patient in CODIACS was given medication or problem-
solving therapy at baseline and then was re-assigned another treatment based on the
response to initial treatment at around 8 weeks after baseline. The objective of the trial
is to maximize the reduction in depression measured by change in the Beck Depression
Inventory (BDI). The AIs embedded in the CODIACS trial are tabulated in Tables 3.1.
The rest of this chapter is organized as follows. Chapter 3.2 introduces the method of
constructing MCB simultaneous confidence intervals. Chapter 3.3 evaluates finite sample
performance of the proposed method using simulation. Chapter 3.4 shows an application




























   Baseline           Stage-1 treatment           Intermediate            Stage-2 treatment                 Primary 
                                 (for 2 months)                  outcome                   (for 4 months)                     outcome 
Figure 3.1. Design structures of the CODIACS trial.
Table 3.1. Multiple comparisons of AIs embedded in CODIACS. The MCB intervals for
AI g compared it with the truly best AI (assuming unknown), whereas the Bonferroni’s
intervals compared each AI with the observed best (g = 5).
Stage-1 Stage-2 Treatment for 80% confidence intervals
AI (g) Treatment non-response response θˆg (sd) δg MCB Bonferroni
1 MED MED MED 6.3 (1.1) 1.98 [-19.7, 0.0] [-25.7, 7.3]
2 MED MED PST 3.3 (1.2) 1.99 [-22.7,-0.3] [-28.7, 4.5]
3 MED PST MED 10.7 (0.6) 2.04 [-15.2, 0.0] [-21.1,11.8]
4 MED PST PST 7.8 (1.1) 1.98 [-18.2, 0.0] [-24.2, 8.8]
5 PST MED MED 15.5 (6.0) 1.71 [ -7.6, 0.0] -
6 PST MED PST 9.5 (1.0) 2.00 [-16.3, 0.0] [-22.2,10.2]
7 PST PST MED 14.2 (6.1) 1.71 [ -8.9, 0.0] [ -3.8, 1.4]
8 PST PST PST 8.2 (1.1) 1.98 [-17.6, 0.0] [-23.6, 9.1]
sd: estimated asymptotic standard deviation of θˆg; MED: medication; PST: problem-
solving therapy.
43
3.2 MCB Simultaneous Confidence Intervals
The proposed method of constructing MCB simultaneous confidence intervals was derived
based on the same setting, notation and model described in Chapter 2.2.1. Let
Θ = (θ1, . . . , θG), where g = 1, . . . , G,
be the vector of the values of all the adaptive interventions embedded in a general two-
stage SMART design as shown in Figure 2.1, arranged in a lexicographical order of
(i; ki1, · · · , kiJi), where g is the AI indicator with value from 1 to G. G is the total
number of AIs embedded in a SMART. For each value of g, let Dg be a (G − 1) × G
contrast matrix such that its g-th column is a (G− 1) vector of 1’s, and its j-th column
is a (G − 1)-vector whose j-th entry is −1 and other entries are 0’s if j ≤ g − 1; whose















g = diag{σig} ·Rg · diag{σig},






. Let δg > 0
be the unique solution to the following equation
P
(∣∣Zig∣∣ ≤ δg; i = 1, . . . , G− 1) = 1− α, (11)
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where α is the familywise type I error rate and






where Rˆg is a consistent estimator of Rg. Here δg is the (1 − α)th quantile of a joint
normal distribution with dimension (G− 1).
The method to construct MCB simultaneous confidence intervals is proposed as fol-
lowing 2 steps:
Step 1: select a subset of AIs, B, defined as
B =
{
g : θˆg − θˆi + δgσˆig/
√
n > 0; g = 1, · · · , G; i = 1, · · · , G; i 6= g
}
.
For the gth AI embedded in a SMART, I construct (G−1) confidence intervals of
(θg−θi)’s, where i = 1, · · · , G and i 6= g, based on the δg obtained from equation
(11). If all these (G − 1) confidence intervals contain upper limits greater than
zero, I select g for B. Otherwise, g is excluded from B. Note that B may include
more than one AI and can not be empty by definition. In a case that an AI has
lower limits greater than 0 when it compares with all the other AIs embedded in
SMART, the subset B is singleton and contains only the AI itself. The subset B
can be viewed as a conservative estimates of the truly best AI.














0, if g = b,
(θˆg − θˆb)− δgσˆgb/
√
n, if g 6= b,
Ugb =

0, if g = b,
min
{




, if g 6= b,
for g = 1, . . . , G and b ∈ B.
By construction, no upper limit of MCB intervals Ug can be positive. This is because
that a MCB interval gives an estimated rage of the value difference between an AI and
the true optimal AI that is assumed to be unknown.
Theorem 3. As n → ∞, [Lg, Ug], g = 1, . . . , G is a set of 100(1 − α)% asymptotic
simultaneous confidence intervals for θg − max
1≤j≤G
θj, j = 1, . . . , G.
The proof of Theorem 3 is given in Appendix 1. An AI with a negative upper limit Ug,
as opposed to having Ug = 0, can be concluded as inferior (to the truly best) with con-
fidence. Furthermore, if the subset B contains only one AI, the MCB interval associated
with this AI must be [0, 0], that is, Lg = 0.
3.3 Finite Sample Performances
3.3.1 SMART Designs and Outcome Scenarios
Simulation study was conducted to evaluated the finite sample performances of the MCB
confidence intervals. Three two-stage design structures were considered in simulation as
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shown in Figure 3.2. The first design structure (DS1) mimics the situation described
in CODIACS trial, in which there are two treatment options at each decision making
point and the intermediate outcomes for both Stage-1 treatment are defined as binary
variable. That is to say, Ti, Rij, Sijk ∈ {0, 1} for i, j, k = 1, 2. DS2 is similar to DS1
but respondents will keep using the same treatment as received in Stage 1. Under DS3,
patients who are randomized to received T1 will be classified as responders and non-
responders. Non-responders will be further randomized to receive 2 treatments at Stage
2, while responders will receive the same treatment as Stage-1 treatment. For those
patients who are randomly assigned to receive T2, they will be given exactly the same










































Design Structure 3 (DS3) 
Figure 3.2. Design structures considered in the simulation.
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Three sets of randomization schemes were considered for each design structure. First,
we considered a balanced randomization (BR) scheme, under which the randomization
probabilities of both treatment coded as 0 and 1 were set to be 0.5. That is to say, at each
randomization point, the chances that a patient was randomly assigned to receive treat-
ment coded as 0 and 1 were equal. Second, we considered an unbalanced randomization
(UBR) scheme, where the randomization probabilities corresponding to the treatment
options coded as 0 were set to be 0.3 and those corresponding to the treatment options
coded as 1 were set to be 0.7. Third, we considered P (V = 0) = P (V = 1) = 0.5 at
Stage 1, while P (V = U |U,X = 0) = 0.3 and P (V = U |U,X = 1) = 0.7 at Stage 2.
Under this randomization scheme, the probability that a responder will receive the same
treatment at Stage 2 as Stage-1 treatment will increase to 0.7 and the probability that
a non-responder will received the same treatment at Stage 2 as Stage-1 treatment will
decrease to 0.3, and thus Stage-1 implements a randomized play-the-winner (RPTW) rule
when the first and the second treatment options are identical. Therefore, the three de-
signs (DS1, DS2 and DS3) and the three randomization schemes (BR, UBR and RPTW)
yielded 9 SMART designs in simulation.
Figure 3.3 gives the 3 outcome scenarios considered for each SMART design. Under
Value Pattern 1 (VP1; top panel), AIs with the same stage-1 treatment had the same
values and AIs started with treatment coded as 1 had greater values comparing to those
started with 0; under VP2, the values of the AIs were uniformly higher if their stage-1
treatment was U = 1; under VP3 (bottom panel), the best AI had stage-1 treatment
U = 1 while the second best had stage-1 treatment U = 0, and so on and so forth,
following an alternating pattern. For each value pattern I considered effect sizes ∆ = 0.05
and 0.10. More details of outcome scenarios see Chapter 2.3.2 and Appendix 2.
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Figure 3.3. Value patterns considered in the simulation.
3.3.2 Simulation Results
I evaluated the finite sample performances of the proposed method to constructure MCB
confidence intervals for identifying inferior AIs: AIs with MCB confidence intervals ex-
cluding zero will be declared as inferior to the truly best AI and removed from further
considerations. To anticipate the clinical context where there are many candidates of the
best AI and the goal is to move forward to the next phase investigation with a subset,
we may consider applying the MCB intervals at a confidence level less than 95% so as
to afford a higher differentiating power. Specifically, I considered 80% confidence in this
simulation.
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Table 3.2. Properties of 80% MCB intervals and simultaneous confidence intervals us-
ing Bonferroni’s adjustment with n = 200: coverage probability (cov) and average
width of intervals (wid).







MCB Bonferroni MCB Bonferroni
cov wid cov wid cov wid cov wid
DS1 VP1 BR 0.927 6.63 0.918 5.42 0.920 6.95 0.918 5.42
UBR 0.941 7.07 0.927 6.31 0.925 7.47 0.927 6.31
RPTW 0.929 7.13 0.920 5.72 0.921 7.52 0.920 5.72
DS1 VP2 BR 0.901 6.64 0.915 8.63 0.867 7.10 0.915 8.65
UBR 0.913 7.24 0.924 9.52 0.873 7.73 0.921 9.53
RPTW 0.907 7.13 0.917 9.57 0.876 7.67 0.916 9.59
DS1 VP3 BR 0.936 6.64 0.905 8.81 0.903 7.30 0.903 8.99
UBR 0.960 7.70 0.919 9.63 0.946 8.37 0.915 9.75
RPTW 0.942 7.10 0.904 9.74 0.914 7.77 0.901 9.90
DS2 VP1 BR 0.881 4.95 0.866 3.90 0.880 5.09 0.866 3.90
UBR 0.885 5.36 0.864 4.80 0.870 5.54 0.864 4.80
RPTW 0.883 5.28 0.858 3.82 0.877 5.44 0.858 3.82
DS2 VP2 BR 0.858 5.00 0.889 5.75 0.848 5.19 0.893 5.88
UBR 0.865 5.30 0.878 6.02 0.846 5.48 0.879 6.11
RPTW 0.838 5.37 0.877 6.47 0.835 5.65 0.882 6.60
DS2 VP3 BR 0.872 4.97 0.873 5.67 0.857 5.23 0.876 5.72
UBR 0.886 5.35 0.876 5.98 0.867 5.67 0.880 6.03
RPTW 0.856 5.30 0.869 6.41 0.840 5.61 0.872 6.45
DS3 VP1 BR 0.806 3.52 0.843 4.00 0.805 3.468 0.841 3.999
UBR 0.813 4.31 0.852 4.79 0.808 4.232 0.852 4.786
RPTW 0.807 3.70 0.843 4.17 0.805 3.643 0.843 4.172
DS3 VP2 BR 0.821 3.66 0.846 4.01 0.815 3.616 0.846 4.022
UBR 0.839 4.55 0.854 4.80 0.828 4.582 0.854 4.815
RPTW 0.821 3.75 0.848 4.19 0.818 3.735 0.850 4.197
DS3 VP3 BR 0.809 3.67 0.841 4.02 0.798 3.664 0.840 4.033
UBR 0.815 4.33 0.845 4.81 0.801 4.390 0.844 4.827
RPTW 0.821 3.94 0.833 4.19 0.800 3.928 0.829 4.209
Table 3.2 gives the coverage probabilities of the 80% MCB intervals under the same
designs and outcome scenarios as in Chapter 3.3.1. To be more concise, each probabil-
ity pertained to simultaneous coverage, and was calculated as the proportion of simu-
lated trials under which the gth MCB interval covers the corresponding true values of
θg −max1≤i≤G θi for all g = 1, . . . , G. Recall that G = 8, 4, 3 under DS1, DS2, and DS3,
respectively. For comparison purposes, I also considered simultaneous confidence intervals
based on Bonferroni’s correction: for each pair of AIs, a confidence interval for the dif-
ference of their values was evaluated with confidence level 100 [1− 0.2/{G(G− 1)/2}] %
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so that the overall nominal coverage is 80%. The coverage probability of the Bonferroni
intervals was calculated as the proportion of simulated trials under which all G(G− 1)/2
intervals covered the corresponding true differences. While I note that the Bonferroni’s
simultaneous confidence intervals address a different estimation problem than the MCB
intervals, both methods are valid in that their corresponding coverage probabilities were
at least 80% in all scenarios. Indeed, both methods appeared to be conservative, es-
pecially under DS1 where there were many AIs. For MCB confidence intervals, the
conservativeness was due to the asymptotic approximation: simulation with larger sam-
ple sizes showed that the coverage probability approached the nominal 80% as the total
sample size n increased.
I also calculated the average widths of the confidence intervals as a measure of effi-
ciency. For the MCB intervals, the average width was taken over the G MCB intervals.
For the Bonferroni’s pairwise intervals, the average width was taken over the G intervals
that compared to the observed best AI. I note that this comparison was unfair against
MCB intervals in two ways due to the interpretations of these intervals. First, the MCB
method did not assume the knowledge of the true best AI, and the calculation of MCB
intervals implicitly accounted for variability induced due to this unknown parameter.
In contrast, the Bonferroni’s method avoided estimating the unknown true best AI by
comparing all AI’s against a known and observed best, and thus was addressing an eas-
ier inferential problem. Second, by definition of the Bonferroni pairwise intervals, the
observed best when compared to itself would have a width of zero, which would arti-
ficially shrink the average width towards a smaller value. However, I opted to use the
Bonferroni’s intervals as a benchmark to evaluate how the MCB intervals perform under
different scenarios. Having noted the difference in interpretations of the two interval es-
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timation procedures and the average widths, I observed that the 80% MCB intervals had
smaller average width than that of the G corresponding Bonferroni’s intervals under value
patterns VP2 and VP3, but had larger average width under VP1. As discussed above,
since the MCB intervals implicitly account for the variability in estimating what the true
best AI is, I would expect larger variability when the true best AI is not unique and thus
difficult to estimate, i.e., under VP1. In practice, scenarios such as VP1 where many
AIs have the same value are conceivably less likely than the other patterns, especially
when the AIs consist of components of different treatment types, such as pharmacological
versus behavioral.
Table 3.3 presents the probability of an AI being declared as inferior to the truly
optimal AI using 80% MCB intervals under balanced randomization with n = 200. Under
the null hypothesis (∆ = 0), where all AIs had the same value, the probabilities of
erroneously declaring an AI as inferior were less than 5% under all design structures. As
the effect size ∆ increased, the truly inferior AIs were correctly identified with increasing
probabilities. Specifically, under ∆ = 0.10 with n = 200, the MCB method identified the
true worst AI as inferior with probabilities between 73% and 98%.
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Table 3.3. The probability of an AI being declared inferior using 80% MCB intervals
under balanced randomization and a total sample size of n = 200.
∆ = 0.00 ∆ = 0.05 ∆ = 0.10
DS1-Null DS1-VP1 DS1-VP2 DS1-VP3 DS1-P1 DS1-VP2 DS1-VP3
AI Value Prob. Value Prob. Value Prob. Value Prob. Value Prob. Value Prob. Value Prob.
(0;0,0) 0.00 0.005 0.00 0.382 0.00 0.461 0.00 0.197 0.00 0.781 0.00 0.857 0.00 0.460
(0;0,1) 0.00 0.006 0.00 0.391 0.87 0.324 0.93 0.098 0.00 0.785 1.23 0.709 1.32 0.236
(0;1,0) 0.00 0.005 0.00 0.379 1.74 0.227 2.49 0.038 0.00 0.778 2.47 0.533 3.52 0.080
(0;1,1) 0.00 0.005 0.00 0.381 2.62 0.156 3.42 0.025 0.00 0.785 3.70 0.361 4.84 0.046
(1;0,0) 0.00 0.006 4.48 0.014 3.63 0.122 -1.24 0.343 6.33 0.015 5.13 0.299 -1.76 0.726
(1;0,1) 0.00 0.006 4.48 0.013 4.50 0.050 0.31 0.115 6.33 0.015 6.36 0.111 0.44 0.334
(1;1,0) 0.00 0.006 4.48 0.015 5.38 0.015 2.49 0.034 6.33 0.017 7.60 0.046 3.52 0.074
(1;1,1) 0.00 0.007 4.48 0.017 6.25 0.001 4.04 0.005 6.33 0.019 8.83 0.000 5.72 0.005
∆ = 0.00 ∆ = 0.05 ∆ = 0.10
DS2-Null DS2-VP1 DS2-VP2 DS2-VP3 DS2-VP1 DS2-VP2 DS2-VP3
AI Value Prob. Value Prob. Value Prob. Value Prob. Value Prob. Value Prob. Value Prob.
(0;0,1) 0.00 0.023 0.00 0.667 0.00 0.734 0.00 0.549 0.00 0.943 0.00 0.976 0.00 0.885
(0;1,1) 0.00 0.023 0.00 0.663 1.92 0.440 3.21 0.119 0.00 0.945 2.77 0.759 4.58 0.191
(1;0,1) 0.00 0.021 4.48 0.033 4.00 0.234 0.40 0.442 6.33 0.034 5.90 0.462 0.57 0.773
(1;1,1) 0.00 0.022 4.48 0.041 5.92 0.001 4.42 0.008 6.33 0.041 8.67 0.000 6.30 0.003
∆ = 0.00 ∆ = 0.05 ∆ = 0.10
DS3-Null DS3-VP1 DS3-VP2 DS3-VP3 DS3-VP1 DS3-VP2 DS3-VP3
AI Value Prob. Value Prob. Value Prob. Value Prob. Value Prob. Value Prob. Value Prob.
(0;0,1) 0.00 0.044 0.00 0.830 0.00 0.820 0.00 0.401 0.00 0.987 0.00 0.983 0.00 0.630
(0;1,1) 0.00 0.045 0.00 0.835 2.59 0.492 -2.97 0.830 0.00 0.987 3.65 0.748 -4.24 0.982
(1;1,1) 0.00 0.042 4.48 0.000 5.17 0.000 2.23 0.001 6.33 0.000 7.30 0.000 3.18 0.000
3.4 Application: Identifying Inferior AIs for Depression Management
Cheung et al. (2015) analyzed data in a subset of patients enrolled to the CODIACS
trial with an objective to further determine which stepped care depression management
regimens should be used and which should be discontinued in an implementation stage.
A specific task may thus be formulated as eliminating inferior AI’s from further practice
based on reduction of Beck Depression Inventory at 6 months, which was the primary
endpoint in the original study. The value of an intervention in this application is the
expected reduction of the depression score. Higher BDI reduction indicates better effect
of depression management, and thus the AI leading to the less BDI reduction is viewed
as inferior to the optimal AI in this case. Furthermore, each AI would adapt to an initial
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response at 8 weeks defined as no increase in depression.
Table 3.1 shows the 80% MCB intervals for the eight possible two-stage AIs embedded
in the study. This analysis identified an inferior AI, namely, the AI with g = 2 that would
start with medication, stay with it upon a non-response, and switch to problem-solving
therapy upon a response. I emphasize that this analysis was not intended to estimate the
true best AI with statistical confidence. Rather, the utility of this analysis is to exclude
the inferior AI from further practice from a quality assurance viewpoint.
As a comparison, I applied the pairwise confidence intervals with Bonferroni’s cor-
rection described in Chapter 3.3.2. Table 3.1 also gives the intervals that compare each
AI with the observed best (g = 5), and shows that the Bonferroni’s correction failed to
differentiate any AIs. From an estimation viewpoint, the MCB intervals give more precise
estimates than Bonferroni’s: the average widths of the 8 MCB intervals was 15.7, and the
average width of the corresponding Bonferroni’s intervals was 25.3, assuming the width
corresponding to g = 5 is 0.
Finally, while the goal of the analysis in this case is not to produce a definitive
statement about whether the eight AIs were significantly different, I also applied the
likelihood-based Wald test proposed in Chapter 2.2 to the CODIACS data for illustration




1.23 0.63 0.37 −0.23 0.00 0.00 0.00 0.00
0.63 1.54 0.01 0.91 0.00 0.00 0.00 0.00
0.37 0.01 0.41 0.05 0.00 0.00 0.00 0.00
−0.23 0.91 0.05 1.19 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 36.42 0.58 36.23 0.39
0.00 0.00 0.00 0.00 0.58 1.03 0.25 0.70
0.00 0.00 0.00 0.00 36.23 0.25 36.95 0.97
0.00 0.00 0.00 0.00 0.39 0.70 0.97 1.28

,
I got the Wald test statistic Q = 36.0 per Equation (6), compared it against a chi-
squared distribution with 5 degrees of freedom according to Theorem 2, and obtained P <
0.001. This analysis thus confirmed that overall the values of the AIs were statistically
significantly different.
3.5 Discussion
I proposed in this chapter an effective tool that can help to identify the AIs inferior to
the truly best AI embedded in a SMART. As one may view a SMART as a study in a
series of experiments, identify the inferior AIs and eliminate them from move forward
can be an temporary goal of an early phase trial of experimental series. When there are
potentially many treatment options, one may want to eliminate inferior AIs often with
a slightly lower confidence level than the conventional 95%. The rationale is that the
clinical investigation can quickly zero in on the promising interventions. At a later phase,
one may aim to perform a selection trial with a goal to move a single AI to the final
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confirmatory stage. Specifically, I considered here 80% confidence level in the simulation
studies and application.
I have developed and extended the distributional theory of MLE for the value of an
AI under general SMART designs in Chapter 2, on which I conducted the inferential
procedure of MCB simultaneous confidence intervals. Similar to the method proposed in
Chapter 2, a gate-keeping test for selecting the best AI in SMART, the proposed method
of constructing MCB intervals can also be generalized to different types of outcomes, such
as continuous, binary and count data. Also, the validity of the method proposed in this
chapter lies on the full specification of the model, which may be perceived as restrictive
in application.
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Chapter 4 SRT - An R Package for Implementing SMART
4.1 Introduction
Motivated by providing a user-friendly statistical software to help clinical investigators
to design and analyze SMART, an R package, SRT (Sequential Multiple Assignment
Randomized Trial), was developed during my thesis research. In this chapter, I will
introduce the usage of this R package using the data from examples in previous two
chapters. Functions built in this R package cover 3 major statistical work in SMART, in-
cluding clinical trial design (i.e., sample size calculation, power calculation), data analysis
(i.e., descriptive statistics, global tests, pairwise tests, simultaneous confidence intervals),
and data visualization (i.e., design diagram, exploratory data analysis). Most commonly
used statistical methods in SMART can be implemented by using this package.
By the time SRT was developed, several R packages related to AI research have been
published on the Comprehensive R Archive Network (CRAN). Some packages had been
developed for the secondary analysis in observational studies, while others were designed
to implement certain analytical methods related to a specific paper. Tang and Melguizo
(2015) developed an R package, DTR (Dynamic Treatment Regimes), for implement-
ing the statistical estimating and testing procedures to compare adaptive interventions
with survival outcomes. Linn, Laber and Stefanski (2015) created an R package, iqLearn
(Interactive Q-Learning), to estimate the values of adaptive interventions based on the
Q-learning method, which allowed to incorporate the impacts from multiple covariates in
estimation and thus can be applied to secondary analysis. Holloway et al. (2017) devel-
oped an R package, named DynTxRegime (Dynamic Treatment Regime), to evaluate
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AI based on observation analysis. A series of methods to estimate the optimal AI in
observational studies were built in this package, including Inverse Probability Weighted
Estimation, IQ-learning, Q-learning, and some other regression-based methods. Wal-
lace, Moodie and Stephens (2017) developed an R package with the name called DTReg
(Dynamic Treatment Regimes Estimation via Regression-based Techniques), including
a series of functions focusing on regression-based estimation and a variance estimation
based on bootstrapping.
Comparing to currently existing R packages related to AI research, the SRT package
has many innovative features. First, it is innovative to build functions that can help
to conduct exploratory data analysis (EDA) for SMART data. There is no R package
so far providing graphical tools to present the features of SMART data in this manner.
EDA techniques are efficient tools to explore the features of clinical trial data at the
beginning of the analysis. SRT allows to output the graphs of descriptive statistics of
SMART data from two different angles, by treatment sequences and by AIs. Also, it can
output the design diagrams of SMARTs, which can not only show the design structures
of SMART data, but also help to design SMARTs. Second, it is innovative to include
functions to construct simultaneous confidence intervals for AI comparisons using SMART
data. It is common to calculate the confidence intervals of group comparisons adjusted
for multiplicity in analyzing RCT data. Unlike the existing packages such that focus
on regression-based methods, SRT allows to output 2 types of simultaneous confidence
intervals for comparing AI values. Third, it is innovative to include functions that helps
to design SMARTs. All the existing R packages focus on data analysis, SRT not only
provides functions to display the design structures of SMARTs, but also can help to
conduct sample size calculation and power calculation in different fashions, which is
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useful at design stage.
The rest of this chapter are organized as follows. Chapter 4.2 illustrates the notations,
which are different from the ones I used in previous two chapters for illustration purpose.
Chapter 4.3 introduces the format of input data. Chapter 4.4 introduces functions for
generating descriptive statistics. Chapter 4.5 illustrates how to compare AIs using func-
tions in SRT, and Chapter 4.6 shows how to use SRT to conduct sample size calculation
and power calculation. Considering the goal of this chapter is to introduce the package
and to illustrate the usage of it, the theoretical and technical details will be skipped.
Readers with interests can find these details in other chapters and appendix.
4.2 Notation
For illustration purpose, the proposed methods in previous two chapters were derived
based on a general two-stage SMART designs, under which the stage-1 treatments are
non-adaptive and the stage-2 treatments are adapted to the categorized intermediate
outcomes. The set of notations
{Ti, Rij, Sijk}, where i = 1, . . . , I; j = 1, . . . , Ji; k = 1, . . . , Kij (12)
were thus used to depict the design structure of a SMART. On the other hand, in clinical
trial practice, it is possible to change certain features of a SMART by controlling the
values of some design parameters. For example, we could design a two-stage SMART,
under which the stage-1 treatment is adapted to the baseline information of individuals,
such as age or disease stage of cancer. Also, it is sometime helpful to design a SMART
with more than two treatment stages due to the AIs of interest. The package SRT can
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handle these variations. To reflect this point, a set of notations that are different from
(12) are used in this chapter. I define a stage as an interval of time during which a patient
receives one specific treatment. For a T -stage SMART with total sample size n, at the
beginning of Stage t, where t = 1, ..., T , an evaluation is made for the lth patient and the
observed result is denoted by Otl. Let Atl be the treatment given to patient l at Stage t.
Also let Yl be the primary outcome observed on patient l at the end of the study. Data
collected from the lth patient who completes a T -stage SMART can be summarized as a
longitudinal trajectory as
{O1l, A1l, ..., OT l, AT l, Yl}, where l = 1, . . . , n. (13)
An over-bar above a Latin letter is used here to indicate the history of certain measures
up to the current time point, at which the event represented by the Latin letter happens.
For example, A¯2l = {A1l, A2l} indicates the history of treatments assigned to the lth
patient up to Stage 2 and O¯2l = {O1l, O2l} represents the results of evaluation for the lth
patient at the beginning of Stage 1 and 2. In this fashion, I can simplify (13) as
{O¯T l, A¯T l, Yl}, where l = 1, . . . , n. (14)
I would further suppress the patient indicator l from these notations for convenience when
it is appropriate, so that (13) and (14) become {O1, A1, ..., OT , AT , Y } and {O¯T , A¯T , Y },
respectively. Let dt(O¯t, A¯t−1) be the decision of selecting action A¯t conditioning on the
clinical history of {O¯t, A¯t−1} by Stage t. An AI is a collection of decisions that can be
denoted by
D = {d1(O¯1); ...; dT (O¯T , A¯T−1)}, (15)
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wherein the stage-specific decision, dt(O¯t, A¯t−1), can be a scalar or vector, depending
on the number of combinations of (O¯t, A¯t−1). For example, an AI in CODIACS can be
{d1; d2(A1 = d1, O2 = 0), d2(A1 = d1, O2 = 1)}, under which the stage-1 decision rule
is a scalar and the stage-2 decision rules is a vector of 2 elements. It is common in
practice to set Ot|(O¯t, A¯t−1) as binary for the purpose of reducing the dimensionality of
SMART data. Also, in some trials (e.g., CODIACS and CHCR), the stage-1 treatment
were designed as non-adaptive. Therefore, O1 does not exist and (13) becomes
{A1l, O2l, A2l, . . . , OT l, AT l, Yl}, where l = 1, . . . , n.
4.3 Input SMART Data
The functions of package SRT require to input wide format SMART data with variables
shown in (16), where Ot is the tailoring variable measured at the beginning of Stage t,
At is the treatment assignment for Stage t for t = 1, . . . , T , and Y is the final primary
outcome. For users who start analyzing a SMART data using SRT, if the original SMART
data are long format, it is required to transform the data into wide format such that each
row of the data represents one patient. Also, if the variable names in the original data
are different from those in (16), it is important to rename the variables as in (16).
{O1, A1, O2, A2, ..., OT,AT, Y }. (16)
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In a case such that the stage-1 treatment is not adaptive to baseline information, there
is no O1 in input data and thus the variables become
{A1, O2, A2, ..., OT,AT, Y }. (17)
For illustration purpose, I generated a pseudo SMART data under the design structure
shown in Figure 4.1, wherein the stage-1 treatment A1 is not adaptive and has two
treatment options, coded as A1 = 0 and A1 = 1. The intermediate outcomes O2 is binary
for both A1 = 0 and A1 = 1, where O2 = 1 for response and O2 = 0 for no response. Given
each combination of (A1, O2), there is always 2 options of stage-2 treatment A2, coded
as A2 = 0 and A2 = 1. Figure 4.2 gives the R programs to generate the pesudo SMART
data. There are 200 patients in this data set. Each patient followed a treatment sequence
(A1, O2, A2). The primary outcome Y is continuous and drawn from a normal distribution
randomly with mean µ = (0, 1.23, 2.47, 3.70, 5.13, 6.36, 7.60, 8.83) and standard deviation
σ = 10. The bottom of Figure 4.2 gives the first 10 rows of this data, with variables A1,
O2, A2 and Y.
Figure 4.1. Design structure of a pseudo two-stage SMART data
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𝐴1 = 0 
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𝑂2 = 1 
𝑂2 = 0 
𝑂2 = 1 
𝐴2 = 0 
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𝐴2 = 0 
𝐴2 = 1 
𝐴2 = 0 
𝐴2 = 1 
𝐴2 = 0 
𝐴2 = 1 
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𝑆112 = 1 
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𝑆212 = 1 
𝑆221 = 1 
𝑅21 = 0 
𝑅22 = 1 
𝑇2 = 1 
Design Structure 2 (DS2) 
𝑆111 = 0 
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𝑅11 = 0 
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Figure 4.2. Generate a pseudo SMART data
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4.4 Descriptive Statistics
Although the ultimate goal of analyzing SMART data is identifying the best (or inferior)
AI based on the statistical inferences of comparing AI values, the first step of analysis in
SMART is usually summarizing the features of data by looking at descriptive statistics.
SRT provides two functions, seqmeans(.) and atsmeans(.), to summarize the sequence-
specific and the AI-specific descriptive statistics. Both functions have options to output
graphs.
An T -stage AI consists of multiple treatment sequences, each of which is indexed by
a series of stage-specific intermediate outcomes and treatments, (O¯T , A¯T ), occurred at
stage t = 1, . . . , T . A patient who completes a SMART will experience one treatment se-
quence. Specifically, which treatment sequence a patient will follow in a SMART, depends
on the results of sequential randomization and the intermediate responses observed on
this patient. The function seqmeans(.) outputs all the treatment sequences embedded
in SMART arranged in the lexicographical order of (O¯T , A¯T ), and returns the descrip-
tive statistics per each treatment sequence. For each sequence, it displays the values of
(O¯T , A¯T ), the number of patients (N), sample mean (MEAN) and sample variance (VAR)
of primary outcome. The option of “family” allows users to specify the type of primary
outcome as either continuous (family=“normal”) or binary (family=“binomial”). The
default of this option is continuous. This function also contains an option “plot” that
allows to choose the output graph. If we choose plot=“d”, the function will give design
diagram of SMART. If choose plot=“s”, the function will give box plots for continuous
primary outcome and bar charts for binary outcome by sequence, depending on the value
of option “family”. The default of option “plot” is design diagram.
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Figure 4.3 shows two examples of outputs of seqmeans(.), using the data of de-
pression management trial (upper panel) and smoking cessation trial (lower panel). The
windows on the left-hand side show the R programs and output descriptive statistics
in console for two examples, where I chose to output graphs of descriptive statistics and
specify family=“normal” for the depression management trial and family=“binomial” for
the smoking cessation trial. Since the primary outcome of depression management trial
is continuous, when I set plot=“s”, it output the box plots by treatment sequence as
shown in the upper-right window. Similarly, since the primary outcome is binary in the
smoking cessation case, the box plots were replaced by bar charts as shown on the lower
right window.
Figure 4.3. Output of function seqmeans(.)
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Figure 4.4 are the design diagrams output by using the function seqmeans(.) with
option plot=“d” for both the depression management trial and the smoking cessation
trial. The dots represent the stage-specific treatments and squares represent the inter-
mediate outcomes. From the design diagram, we can see that there are two treatment
options at all the decision making points and the intermediate outcomes are binary in the
depression management trial. While, there are four stage-1 treatment options and the
intermediate outcomes are also binary for the smoking cessation trial. In addition, for
each decision making point at Stage 2, there are two treatment options in this case. Both
the stage-1 treatments in the depression management trial and the smoking cessation
trial are not adapted to the baseline information. The lines connecting the stage-specific
treatment and intermediate outcome from left to the right correspond to one treatment
sequence. It can see that there are totally 8 treatment sequences in the left diagram and
16 treatment sequences in the right diagram.
Figure 4.4. Design diagram by seqmeans(.)
It is important to estimate the values of AIs and observe the pattern of these estimates.
The R package SRT uses a function atsmeans(.) to estimate AI values. There are sev-
eral options provided by this function that allow users to customize the outputs based on
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the interests of studies. By specifying the option of method=“MLE” or method=“IPW”,
I can choose to use maximum likelihood estimator or inversed probability weighting esti-
mator for estimation. The default of this option is MLE. This function also provides an
logic option “common” so that users can choose to apply the common variance across all
the treatment sequences for estimation. This function also gives an logic option “conf” for
users to choose whether the output of estimated AI values are with confidence intervals.
Users can control the confidence levels of these intervals at (1− α)% level by specifying
the numeric option “alpha”. The function atsmeans(.) outputs 3 parts of contents. First,
it outputs the value matrix, in which each row represents one AI. Therefore, for a SMART
with total number of G AIs embedded in, the value matrix always have G rows. For each
row, the decision makings under the corresponding AI are listed and it also shows total
number of patients following the AI, estimated AI value, standard error of estimation and
confidence intervals (if specify “CI=True”). This function also automatically outputs the
estimated variance-covariance matrix for the estimated values of all the AIs embedded
in SMART. For a SMART with G AIs, the variance-covariacne matrix has a dimension
of G×G. The functions provides a logic option “plot”. If users specify “plot=True”, it
output a figure of all the estimated AI values with (1− α)% level confidence intervals.
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Figure 4.5. Estimated AI values by atsmeans(.)
Figure 4.5 shows the outputs of the function atsmeans(.) using the two example
data mentioned before. The upper-left window is the program and output of calling the
function using the depression management trial data. There were up to 8 AIs embedded
in this SMART data. I use g = 1, . . . , 8 as the index of AI. For example, there were 49
patients in this dataset followed the AI with g = 1. The estimated value of this AI is
6.27 with 95% confidence interval (4.10, 8.44). The plot of these AI values is shown on
the upper-right window. The estimated variance-covariance matrix is shown below the
value matrix. We can see that the estimated variances corresponding to AIs with g = 5
and g = 7 are larger than others. The covariances between AIs with different stage-
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1 treatment are consistently equal to zero. The lower-left window is the program and
output of using the smoking cessation data, which has binary primary outcome. When
we specify the option “family=binomial”, the calculation will automatically assuming
uncommon variance across all the treatment sequences. The 16× 16 estimated variance-
covariance matrix is also given in the output. We can see that the block diagonal matrices
are non-zero, while others are all zeros. The value plots of this example is shown in the
lower-right window, with the observed best AI with the index g = 1 being the one has
greatest estimated value and g = 8 with the smallest estimated value.
4.5 Comparing Multiple AIs
SMART is an efficient design for early phase clinical trials. The goals of these studies
are usually providing information about selecting one promising or several near-best AIs
and moving forward to further clinical investigation, in which a confirmatory trial will
be conducted by comparing the selected AI(s) with a appropriate reference intervention.
In these situations, the key of statistical analysis is comparing the values of multiple AIs
embedded in SMART. Several analytical methods can be applied to do this job, such as
the omnibus test mentioned in Chapter 2.2 and pairwise comparison testing procedure
described in Chapter 2.3. Another technique can be building a series of simultaneous
confidence intervals, such as the MCB confidence intervals introduced in Chapter 3. The
package SRT uses a function called smartest(.) to make such comparisons.
Same as the functions of seqmeans(.) and atsmeans(.), the function smartest(.) also
provides options “family” for users to specify the type of primary outcome, “method” to
select the estimation method, and “common” to choose whether the common variance
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assumption across all treatment sequences should be applied. This function automatically
outputs three parts of results, which are the list of all AIs, results of the global test, and
pairwise comparisons. First, it gives a list of AI under “$Strategy”, which provides the
information of all the AI embedded in the input SMART data and the decision makings
under each AI. The total number of patients under each AI is also given in the last column
of this section. In the second section of output, this function gives the results of a global
test with the hypothesis
H0 : µ1 = · · · = µG versus H1: µg’s are not all equal for g = 1, . . . , G.
For a SMART consists of a large number of AIs, such a global test can be applied as the
gate-keeping test to avoid exhaustive search, so as to control the familywise type I error.
The details of conducting such a global test is described in Chapter 2.2 and Chapter
2.3. Under the output “$Global.test”, it gives the information about the total number of
patients participated in a SMART, total number of AIs embedded in the SMART data,
degrees of freedom, test statistics and P-value of this test. The third part of output
gives a matrix of the results of pairwise comparisons. For a SMART data include G AIs,
there are G× (G− 1) pairwise comparisons. Each row of this section corresponds to one
pairwise comparison and it provides information of the indexes of two AIs, the difference
of two AI values with a (1 − α)% level confidence interval, the test statistics and the
P-value of the pairwise comparison with the hypothesis
H0 : µj = µk versus H1: µj 6= µk, where j, k = 1, . . . , G and j 6= k.
The function smartest(.) provides an option “adjust”, by which users can control the type
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of confidence intervals given in the output. The default of this option is “adjust=n”, which
gives the confidence intervals without adjusting for multiplicity. If specify “adjust=Bon”,
the function will return confidence intervals adjusted for Bonferroni correction. By de-
fault, for a SMART data including G AIs, the confidence intervals will adjusted for
G×(G−1)
2
pairs of comparisons. In practice, users can control the number of pairwise com-
parisons in multiplicity adjustment by specifying a value to an option named “npairs=”.
Users can also choose “adjust=MCB”, which leads to MCB intervals in the output. Since
MCB confidence intervals are comparing each AI value with the truly best AI, which is
assumed to be unknown in analysis, for a SMART data with G AIs, there are G MCB
confidence intervals. Consequently, When the “adjust=MCB” is specified, there are only
G rows in this section of output and each row corresponds to one AI.
Figure 4.6 shows the outputs of comparing AIs embedded in the smoke cessation trial
data based on the function smartest(.). There are 4 options for stage-1 treatment. From
the first part of output, users can see that there are 16 AIs and the decision makings under
each AI. Each stage-1 treatment option corresponds to 4 AIs. The second part gives the
results of the global test. It shows that there are 282 patients who completed this SMART
and totally 16 AIs embedded in the study design. The test statistics of this global test
calculated based on the sample data is 19.14 and it follows a chi-squared distribution
with 11 degrees of freedom under the null hypothesis of no difference among all the AI
values, which leads to a P-value equal to 0.0587. Therefore, I conclude that the AI values
are not statistically different among all the 16 AIs embedded in the study at 5% nominal
significance. The third part of the output gives the results of pairwise comparisons. For
example, the first row gives the difference of values of AIs g = 1 vs. g = 2, where g = 1 is
the AI of (1; 0, 0) and g = 2 is the AI of (1; 0, 1). This part of output shows that the value
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difference is 0.01 with a 80% confidence intervals (−0.24, 0.25) adjusted for Bonferroni
correction. Since no value of “npair” is specified, the simultaneous intervals is adjusted for
16×15
2
= 120 pairwise comparisons. There are 16×15 = 240 rows in this section of output.
Figure 4.7 is the output of “$pairwise.comparisons” when choose “adjust=MCB” using
the depression management trial data. In this case, I am not comparing two observed AI
values, but comparing the value of each AI with the unknown truly best AI. There are
totally 8 rows in these output and the MCB interval of AI with g = 2 has an upper limit
with negative value. Therefore, we identify this AI as inferior to the truly best AI.
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Figure 4.6. Compare multiple AIs using the smoking cessation trial data by smartest(.)
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Figure 4.7. MCB intervals using the CODIACS data by function smartest(.)
4.6 Sample Size Calculation
The goal of sample size calculation in planning a SMART is to estimate the minimal
required sample size that can help to achieve the targeted comparative power under the
rigorous control of the pre-specified error rate. In practice, the sample size calculation is
based on the planned analytical method decided at the design stage. The package SRT
provides a function, smartsize(.), to conduct the sample size calculation.
This function allows to choose whether to conduct the sample size calculation based
on a global test, or a pairwise test between two pre-specified AIs. Users can use the logic
option “global=” to control the test by which the sample size calculation is conducted.
The default is “global=True”. By specifying the values of two options “alpha=” and
“beta=”, users can control the targeted type I error rate at α and targeted power at
(1 − β) × 100%. The default of these two options are “alpha=0.05” and “beta=0.20”.
When users choose “global=True”, there are two choices to input the required information
for sample size calculation. First, users can directly input the standardized effect size
(∆) via the option “delta=” and the degrees of freedom of chi-squared test (ν) via the
option “df=”. The details of how to calculate the effect size and degrees of freedom
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are described in (9) and (7) in Chapter 2.2. Alternatively, investigators can input the
sequence information matrix (SIM) by an option “sim=”, which is a data frame contains
all the sequence-specific information as shown in Figure 4.8. Each row of SIM represents
a treatment sequence in SMART. The columns of SIM include the index of sequence
(SEQ), the baseline and intermediate outcomes variables (O1, O2, . . . , OT ), the response
rates (P1, P2, . . . , PT ), the stage-specific treatments(A1, A2, . . . , AT ), the randomization
probabilities (PI1, P I2, . . . , PT ), and the targeted sequence-specific mean (MEAN) and
standard deviation (SD).
Figure 4.8. Sequence information matrix (SIM)
Figure 4.9 is the R inputs and outputs of using smartsize(.) to calculation the sample
size for a SMART. The sequence information matrix (sim3) is shown in Figure 4.8. This is
a 2-stage SMART with stage-1 treatment not adapted to baseline information. Thus, the
stage-specific treatment and intermediate response can be summarized by (A1, O2, A2).
There are 8 treatment sequences embedded in the design. The targeted mean and the
targeted standard deviation for each sequence are specified in the last two columns of the
matrix. The effect size calculated based on sim3 is ∆ = 0.0435 and the degrees of freedom
of chi-squared test is df=5. By inputing the targeted effect size and degrees of freedom
into smartsize(.), I knew from the R output that the total sample size of 295 patients will
help to achieve 80% power. I also directly input the sequence information matrix (sim3),
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and it gave the same results. In practice, sequence information matrix is helpful when
statisticians communicate with clinical investigators. It displays the clinical history of
each type of patients during the trial in a straightforward manner, so investigators can
have better sense in setting up the targeted means and standard deviations at design
stage.
Figure 4.9. Sample size calculation by smartsize(.)
In some case, the investigator is particularly interest in comparing a pair of AIs. By
specifying the option “global=FALSE”, the function smartsize(.) will return the sample
size calculated based on a pairwise test and return the total numbers of patients included
in the pair of AIs of interest. The total sample size of SMART can be obtained by
adjusting the size of pairwise test based on the randomized probabilities determined at
design stage. In that situation, the sample size calculation is similar to a traditional t
test.
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Chapter 5 An Exploratory Study to Design a SMART for Comparing Mul-
tiple Patient Care Strategies for Depression Management
5.1 Introduction
I explored the distribution theory of maximum likelihood estimators (MLEs) of adaptive
intervention (AI) values under general SMART designs and proposed a Wald test for
overall equality based on MLEs in Chapter 2. Such a test can be applied as a gate-
keeping test for comparing multiple AIs embedded in a SMART. Another important
contribution of the proposed test is that we can use the formal sample size calculation
formula and power calculation formula derived based on the proposed Wald test to design
a SMART. In this chapter, I will show an example about how to design a SMART for
comparing multiple patient care strategies against depression.
It is common for patients to suffer from depression after the surgeries for acute coro-
nary syndrome (ACS) (Bush et al., 2005). A comprehensive review noted that there are
almost 2 out of every 5 post-ACS patients have clinically significant depression (Carney
and Freedland, 2008), which has been reported to be observationally associated with
diminished health-related quality of life (Stafford et al., 2007), high costs (Von Korff et
al., 1992) and poor medical prognosis (Nicholson, Kuper and Hemingway, 2006). Conse-
quently, a patient care strategy, named screen and treat, which recommends administering
a depression screening questionnaire to post-ACS patients and referring those who are
positive in the screen for depression treatment, has been incorporated into the guide-
lines from the American Heart Association (AHA) and endorsed by multiple societies
(Lichtman et al., 2008; Graham et al., 2007; National Institute for H, Clinical E, 2009).
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However, there is no randomized clinical trial (RCT) to inform such a large scale and
potentially expensive patient care strategy. Evidence-based clinical guidelines typically
review all available research on a specific topic systematically and make recommendations
by integrating such information. Comparing to observational studies, RCTs are usually
more replicable, have fewer sources of bias and strong ability in controlling statistical
power and error, and thus are given greater emphases as evidences for practice guidelines
(Guyatt et al., 2000). The study in this chapter was motivated by the needs for design-
ing a RCT to evaluate the net benefit of AHA screen and treat strategy and compare it
with other two common post-ACS patient care strategies. As the AHA screen and treat
strategy involves two clinical actions given sequentially over a period of time and the
subsequent action (i.e., referral to treat or not) taken by a patient depends on the result
of the first action (i.e., depression screen) within the same individual, a patient under
this strategy will follow one of two clinical sequences, “depression screen → negative →
notification” and “depression screen → positive → referral to treat”. Thus, it fits the
adaptive intervention paradigm. See Chapter 1 for more details about AI definition and
Cheung et al. (2015) for an example of AI in depression management. Specifically, I am
interested in designing a RCT for comparing the AHA depression screen and treat strat-
egy (experimental strategy) with the no screening strategy (inactive control), because no
RCT on depression screen for post-ACS patients has been conducted. In addition, we
are also interested in a minimal enhanced strategy, called screen and notify (active con-
trol), which provides all post-ACS patients depression screen and notifies the appropriate
in-network primary care provider (PCP) of the existence of depression. The primary out-
come considered for this study is the improvement of quality-adjusted life year (QALY)
at 18 months after baseline. A strategy leading to a greater improvement of QALY is
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viewed as a better patient care strategy.
5.2 Study Designs: SMART vs. RAB
I illustrate in this section two different clinical trial designs with the goal to compare the
3 patient care strategies mentioned in Chapter 5.1. A clinical trial named Comparison of
Depression Interventions after Acute Conorary Syndrome - Quality of Life (CODIACS-
QOL), was originally proposed to compare the three patient care strategies of interest.
Based on the design of this trial proposed in protocol, patients were randomly assigned
to 3 arms at baseline with equal probabilities. Each treatment arm corresponded to one
patient care strategy as shown in Figure 5.1. Such a randomized at baseline (RAB) design
helps to rule out the possible impacts from unmeasurable confounders. As a result, data
collected using RAB design allow to make comparisons among 3 strategies with minimal
bias; and in principle, the results could be referred for evidence-based practice guideline.
Those patients who are screen negative in both the experimental group and the active
control group would have the exactly same clinical experience (i.e., depression screen →
negative → notification) during the study, and thus it is reasonable to expect that the
primary outcomes of these patients are identically distributed. However, under such a
design, only a portion of patients who followed this sequence contributed in estimating
the effect of either the experimental strategy or the active control strategy, which can
possible lose efficiency.
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Figure 5.1. Design diagrams for comparing 3 patient care strategies after ACS: Ran-
domized at baseline (RAB)
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Alternatively, w ca design a SMART o compare the 3 strategies of interest as
shown in Figure 5.2. Under the SMART design, a patient is initially randomized to
receive depression screen or no scre n, and then re-randomized at the subsequent stage
to receive treatment directly or to be notified about the existence of depression. By
virtue of sequential randomization, the assumption of ignorable treatment holds and thus
the results can be referred as RCT-based evidence for practice guideline. Patients who
complete the SMART design can possibly follow 4 clinical sequences: (1) no depression
screen, (2) depression screen → negative → notification (3) depression screen → positive
→ notification and (4) depression screen → positive → referral to treat. Comparing to
the RAB design, data collected from all the patients who screen negative in SMART
contribute to evaluate both the experimental strategy and the active control strategy,
and thus can potentially improve the design efficiency.
It is important to note that this SMART design involves AIs with different types
of structures, featured by 3 parameters: the number of stages, the number of action
options given clincial history, and the number of intermediate response categories. This
is different from the traditional SMART research focusing on comparing AIs with the
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same structure (Robins, 1986; Lavori et al. 2007; Murphy et al. 2001). I have shown in
Chapter 2.3 that the proposed Wald test is valid for SMART designs with varying design
structures and randomization schemes, and thus it can be applied to the design shown
in Figure 5.2. However, whether we can design a SMART trial to improve some desired
features, such as power or average patient care, comparing to the RAB design proposed
in original protocol, remains unclear. In this chapter, I explore various combinations of
randomization probabilities that yield different powers of SMART designs.
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Figure 5.2. Design diagrams for comparing 3 patient care strategies after ACS: Sequen-
tial Multiple Assignment Randomized Trial (SMART)
5.3 Notation and Method
5.3.1 Notation
I use the same notations under the general SMART design as described in Chapter 2.2.1.
Given the design structure shown in Figure 5.2, let T1 and T2 denote without depression
screen and with screen, respectively, at Stage 1. Under T2, there are two possible response
categories, R21 for screen negative and R22 for screen positive. While under T1, all the
patients have the same intermediate outcome R11. Given the clinical history of (T2, R22),
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patients are randomized to two Stage-2 actions, S221 for notification and S222 for referral
to treat. Also, I use S111 and S121 to represent the Stage-2 action for those with history
(T1, R11) and (T2, R21). Specifically in the data, I code 1 for depression screen and 0 for
no screen. Also, I code 1 for referral to treat and 0 for notification for those who screen
positive at Stage 2. I use 0 to represent screen negative and 1 screen positive. In addition,
those who receive no screen do not have any screen result (coded as 0) or action (coded
as 0) at Stage 2. Thus, the design structure of SMART can be summarized as
(T1, T2) = (0, 1)
(R11, R21, R22) = (0, 0, 1)
(S111, S211, S221, S222) = (0, 0, 0, 1).
Let (pi1, pi2) be the Stage-1 randomization probabilities corresponding to (T1, T2). Let
(pi221, pi222) be the Stage-2 randomization probabilities for (S221, S222). Considering that
both (pi1, pi2) and (pi221, pi222) sum up to 1, given the design structure in figure 4.2, the
SMART design is completely depicted by (pi2, pi222). I denote the screen and notify strat-
egy by (1; 0, 0) and the AHA screen and treat strategy by (1; 0, 1). Also, under the
SMART framework, we can view the no screen strategy as a degenerate case of AI, and
thus denote it by (0; 0, 0).
5.3.2 Analytical Methods
The CODIACS-QOL protocol proposed to compare three strategies by pairwise testing
procedure. Specifically, t-test with Bonferroni adjustment was used to compare each pair
of strategies. Since this is a classic testing procedure used in traditional RCT, I skip the
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details of the test. For SMART design, I apply the likelihood-based Wald test described
in Chapter 2.2. Let Θ = (θ1, θ2, θ3) be the values of 3 AIs (i.e., no screen, screen and
treatment, screen and treat) embedded in the study. A Wald test is proposed with the
following hypotheses:
H0 : θ1 = θ2 = θ3 versus H1: θg’s are not all equal for g = 1, 2, 3. (18)
Let n be the total sample size of a SMART. Let
C =
 1 −1 0
1 0 −1

be the contrast matrix. Let Θˆ be the MLEs of Θ and Σˆ be the estimated asymptotic
covariance matrix of Σˆ. A Wald-type test statistic can be written as
Q = n(CΘˆ)T (CΣˆCT )−(CΘˆ), (19)
whereM− denotes a generalized inverse of a square matrixM . Under the null hypothesis
of (18), the test statistics Q









Ji + I − 1 = 4− 3 + 2− 1 = 2. (20)
While, under the alternative hypothesis of (18), Q
d−→ χ2ν(λ∗), a noncentral chi-squared
distribution with noncentrality parameter λ∗. I have shown in Chapter 2.3 that this test
has nice asymptotic properties and performances under SMART designs with varying
design structures and randomization schemes. More details of the test see Chapter 2.2.
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5.3.3 Power Calculation
The power of the Wald test given the targeted response probabilities {pij} and targeted
sequence-specific outcome parameters {φijk, τijk} can be calculated as follows:
Step 1: Given the design structure {Ti, Rij, Sijk} and a pre-specified type I error rate α,
get the critical value (CV ) of rejecting H0 in (18) by
CV = χ2ν,α.
Step 2: Given total sample size n, randomization probabilities {pii, piijk} and targeted










where Θ∗ is the targeted AI values and Σ∗ is the targeted asymptotic covariance
matrix of MLEs.
Step 3: Given ν, λ∗ and CV , calculate the power by
Power = 1− Pr(χ2ν,λ∗ ≤ CV ). (21)
Note that Σ∗ is a function of {pii, piijk} given {Ti, Rij, Sijk, } and {pij, φijk, τijk}, so
that λ∗ is a function of {pii, piijk}, and thus, the power of Wald test given {Ti, Rij, Sijk, }
and {pij, φijk, τijk} is a function of {pii, piijk}.
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5.4 Compare Designs by Numerical Computation
In this section, I compare SMART versus RAB by numerical computation. The goal is
to explore the possibility of improving some desired features of RCT by replacing the
original proposed RAB design with a SMART design. Specifically, I compare several
SMART designs with different randomization probabilities (pi2, pi222) versus the RAB
design proposed in CODIACS-QOL protocol under difference outcome scenarios in terms
of type I error rate, comparative power, and average primary outcome of all the trial
participants.
5.4.1 Outcome Scenarios
I considered 9 outcome scenarios using 3 screen positive rates P = (0.1, 0.2, 0.3) and
3 value patterns (VP) of targeted treatment sequence-specific means suggested by the
CODIACS-QOL protocol. The final primary outcome Yijk given the clinical history of
(Ti, Rij, Sijk) was randomly generated based on a normal distribution with sequence-
specific means
VP1: (φ111, φ211, φ221, φ222) = (0.055, 0.055, 0.055, 0.21)
VP2: (φ111, φ211, φ221, φ222) = (0.055, 0.055, 0.080, 0.21)
VP3: (φ111, φ211, φ221, φ222) = (0.055, 0.055, 0.130, 0.21)
and sequence-specific variance σ2 = 0.172. φijk was specified by
φijk = β0 + β1Ti + β2Rij + β3Sijk + β4TiRij + β5TiSijk + β6RijSijk + β7TiRijSijk
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for Ti, Rij, Sijk ∈ {0, 1}, and the details of choice β’s see Appendix A2. Under VP1,
the depression screen itself has no impact on primary outcome so that the post-ACS
patients under the no screen strategy have the same expected outcome as those under
the screen and notify strategy. In other words, the improvement of primary outcome
for those patients under the AHA screen and treat strategy is completely due to the
action of referral to treat. Under VP2, the screen and notify strategy has mild positive
impact on the primary outcome, comparing to those under no screen strategy. But the
improvement of outcome is mainly driven by the action of referral to treat. Under VP3,
notifying patients the existences of depression has strong impact on primary outcome.
Figure 5.3 shows the AI values in all 9 outcome scenarios, with each row corresponding
to a value pattern and each column corresponding to a screen positive rate.
86
Figure 5.3. Outcome scenario of AIs considered in the simulation. (0;0,0) is no screen
strartegy; (1;0,0) is screen and notify strategy; (1;0,1) is screen and treat strategy.
5.4.2 SMART Design
For each outcome scenario, I calculated the theoretical powers by (21) under each pair
of (pi2, pi222) with values varying from 0.01 to 0.99. The type I error rate was set to be
α = 0.05 and the total sample size was fixed at n = 400. Figure 5.4 gives the surface
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plots of theoretical powers under each pair of (pi2, pi222). Under VP1 and VP2, given a
certain value of pi222, the power increases as pi2 increases. While given pi2, pi222 = 0.5
achieves the maximum power. Under VP3, when the screen positive rate is P = 0.1,
the power varies by (pi2, pi222) in the same style as under VP1 and VP2. When P = 0.2,
the randomization probabilities pi2 with a value between 0.6 to 0.8 results in a greater
power than other values. When P = 0.3, pi2 with a value between 0.5 and 0.7 results
in a greater power than other values. I selected 5 SMART designs (S1-S5) under each
outcome scenario as shown in Table 5.1. For VP1 and VP2, pi222 was fixed at 0.5 and
pi2 took a value of 0.5-0.9 with 0.1 increment in S1-S5. For VP3, with P = 0.1, I used
the same designs as VP1 and VP2; while with P = 0.2 or 0.3, I chose 5 combinations
of pi2 and pi222 values that can yield high power as depicted in Figure 5.3. I evaluated
the actual type I error rates, empirical powers and average primary outcomes of these
SMART designs and compared them with the RAB design described in Chapter 5.2.1
using simulation. For each simulated SMART data, I conducted a proposed Wald test
as described in Chapter 2.2. For each simulated RAB data, I conducted pairwise t tests
with Bonferroni adjustment. All the simulation results were generated based on 5000
replicates.
Value Pattern Screen Positive Rate S1 S2 S3 S4 S5
VP1 P=0.1 (0.5,0.5) (0.6,0.5) (0.7,0.5) (0.8,0.5) (0.9,0.5)
P=0.2 (0.5,0.5) (0.6,0.5) (0.7,0.5) (0.8,0.5) (0.9,0.5)
P=0.3 (0.5,0.5) (0.6,0.5) (0.7,0.5) (0.8,0.5) (0.9,0.5)
VP2 P=0.1 (0.5,0.5) (0.6,0.5) (0.7,0.5) (0.8,0.5) (0.9,0.5)
P=0.2 (0.5,0.5) (0.6,0.5) (0.7,0.5) (0.8,0.5) (0.9,0.5)
P=0.3 (0.5,0.5) (0.6,0.5) (0.7,0.5) (0.8,0.5) (0.9,0.5)
VP3 P=0.1 (0.5,0.5) (0.6,0.5) (0.7,0.5) (0.8,0.5) (0.9,0.5)
P=0.2 (0.8,0.5) (0.8,0.6) (0.7,0.7) (0.65,0.8) (0.6,0.9)
P=0.3 (0.7,0.5) (0.7,0.6) (0.65,0.7) (0.6,0.8) (0.55,0.9)
Table 5.1. Randomization probabilities (pi2, pi222) considered in each outcome scenario
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Figure 5.4. Theoretical powers of the Wald test by randomization probabilities.
5.4.3 Comparison Results
Table 5.2 gives the actual type I error rates of applying the Wald test to SMART designs
(S1-S5) at 5% nominal level. Each row in this table corresponds to an outcome scenario
described in Chapter 5.4.1. All these actual type I error rates are fairly close to the nom-
inal level of 5%. For comparison purpose, I also considered pairwise testing procedures
comparing 3 strategies under the RAB design, with or without multiplicity adjustment.
89
The pairwise testing procedure without multiplicity adjustment would reject H0 in (18)
if any pairwise test has a P-value less than 0.05. As expected, such a procedure led to
inflated type I error rates up to 0.12-0.13. For the pairwise testing procedure adjusted
for multiplicity, I used the Bonferroni’s correction and adjusted the significance level for
each individual test for 3 comparisons. Consequently, a P-value less then 0.0167 would be
needed to claim overall significant. The pairwise tests with multiplicity adjustment under
RAB design led to actual type I errors rate close to 0.045, which was slightly conservative
than the Wald test applied to SMART designs.
Table 5.2. Type I error rates of the Wald test applied to SMART designs and the pair-
wise tests with and without multiplicity adjustment applied to RAB design at 5% nom-
inal significance (total sample size n = 400)
Pairwise test (RAB) Wald test (SMART)
VP Screen Positive Rate Unadjusted Adjusted S1 S2 S3 S4 S5
VP1 P=0.1 0.125 0.044 0.051 0.047 0.045 0.052 0.052
VP1 P=0.1 0.125 0.044 0.051 0.045 0.046 0.052 0.052
VP1 P=0.1 0.125 0.044 0.051 0.046 0.045 0.052 0.052
VP2 P=0.2 0.122 0.045 0.050 0.049 0.049 0.051 0.051
VP2 P=0.2 0.122 0.045 0.050 0.049 0.049 0.051 0.051
VP2 P=0.2 0.122 0.045 0.050 0.049 0.049 0.051 0.051
VP3 P=0.3 0.120 0.043 0.050 0.051 0.048 0.048 0.052
VP3 P=0.3 0.122 0.045 0.050 0.049 0.049 0.051 0.051
VP3 P=0.3 0.122 0.045 0.050 0.049 0.049 0.051 0.051
Figure 5.5 compares the empirical powers of Wald test applied to SMART designs
(S1-S5) versus those of pairwise tests with Bonferroni’s correction under RAB design in
each outcome scenario. The top panel corresponds to VP1 with screen positive rate equal
to 0.1, 0.2 and 0.3, respectively. The empirical powers of Wald test in these settings are
consistently greater than those of adjusted pairwise tests in RAB designs. The powers
of both Wald test in SMART and adjusted pairwise tests in RAB design increase when
the screen positive rate increases (from left to the right). This is because the effect size
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increases as the screen positive rate increases given fixed sequence-specific means φijk’s.
S5 achieves the greatest power in each scenario under VP1, which is consistent with the
trends of theoretical powers observed in Figure 5.4. The trends of empirical powers under
VP2 (second panel) are similar to those under VP1, but the powers under VP2 is lower
than those of the same designs under VP1 given a screen positive rate. This is mainly
due to smaller effect size under VP2 than that under VP1. Under VP3 (bottom panel),
the trends of empirical powers are different from those under VP1 and VP2, as S5 is not
always the SMART design with the greatest power. The best SMART design are S5, S1
and S3 for screen positive rate P = 0.1, 0.2 and 0.3, respectively, among the 5 designs
(S1-S5) we considered in simulation.
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Figure 5.5. Empirical powers of Wald test applied to SMART designs (s1-S5) and ad-
justed pairwise tests applied to RAB design at 5% nominal significance (n = 400).
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Figure 5.6. Average primary outcome of patients who participated in SMART and
RAB designs considered in the simulation.
Figure 5.6 gives the average primary outcomes of simulated trials under different
SMART designs and the RAB design in 9 outcome scenarios. A RCT design with higher
average primary outcome is regarded to be more beneficial for trial participants and thus is
more recommendable ethically. To get the average primary outcome of a specific design
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in each scenario, I first calculated the average primary outcome over all the subjects
in a simulated trial, and then calculated the average outcome across 5000 simulation
replicates. Figure 5.6 shows that although some SMART designs (e.g., S1 under VP1
with screen positive rate P = 0.1) have lower average primary outcome values comparing
to RAB design, I was able to identify at least one SMART design with better average
outcome values than the RAB design in all 9 outcome scenarios. In general, the higher
proportion of patients referred to treat when the existences of depression are identified
by screen, the better average primary outcome a SMART design yields in this case.
4.5 Discussion
SMART is typically considered as a clinical trial design for comparing multi-stage treat-
ment strategies for chronic diseases. For example, in the SMART for comparing two-stage
AIs for lymphoma patients (cf. Figure 1.2), a patient received one specific treatment for
a period of time in both Stage 1 and Stage 2. In this chapter, we show that SMART can
be applied in a more flexible manner. Although the AHA screen and treatment strategy
and the screen and notify strategy only involve one treatment, as long as the strategy
involves in multiple clinical decisions and the subsequent decision depends on the prior
decision and the results of the prior action, we can applied a SMART design and enjoy
the advantage of sequential randomization. Specifically, in the example shown in this
chapter, comparing to the traditional RAB design original proposed in protocol, we can
design a SMART to answer the same research question with better power and average
primary outcome, thus improve the efficiency and quality of patient care.
I explored the possibility of designing a SMART to improve the efficiency and pa-
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tient care in clinical trial. I used grad search to identify the randomization probabilities
(pi2, pi222) of SMART yielded high powers. However, the quantitative relationship between
randomization probability and the optimal power given intermediate response rates Pij
and sequence-specific parameters of outcome (φijk, τijk) remains unclear. Also, when the
design structure becomes complicated, the vector of randomization probabilities used to
depict the SMART design will increased from 2 to higher dimension. How to efficiently
identify the randomization probabilities that help to achieve the most desired features of
a SMART in those situations? These are important problems for my next step study in
the future.
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Chapter 6 Conclusion and Future Directions
Motivated by developing methods to control the false positive finding in a pre-specified
level and improve the power for comparing multiple AIs in SMART, I have proposed
methods to address these problems from two different angles, selection and screening.
For selection, I proposed a likelihood-based Wald test that can be applied as a gate-
keeping test to select the best AI and study it properties. For screening, I development
a method to build simultaneous confidence intervals that can help to identify inferior AI
efficiently. As one may view SMART as a clinical trial design at the early phase in a series
of experimental studies, selecting the best AI to move it forward and identifying inferior
AIs from further investigation represent two ends on this spectrum of experimental series.
The concepts of selection and screening are well-studied in the contexts of clinical trial
research for non-adaptive interventions (e.g., Bechhofer, Santner, and Goldsman, 1995;
Thall, Simon, and Ellenberg 1988; Cheung 2008). A contribution of my dissertation
research is to extend these concepts to the evaluation of adaptive interventions, and thus
enhance the practicality of SMART. In the early phase trial where there are potentially
many treatment options, one may want to eliminate inferior AIs. I proposed a method
to build MCB intervals that can be used to quickly screen SMART data and identify
inferior AIs. At the later phase, one may aim to perform a selection trial with a goal
to move a single AI to the final confirmatory stage, for which I proposed a gate-keeping
Wald test. I also derived a formal sample size calculation formula, which can be used to
calculate sample size in designing SMARTs.
I developed and extended the distribution theory of MLE for the value of AIs em-
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bedded in general SMART designs. The theory also lends itself the proposed inferential
procedures – the gate-keeping test and the MCB simultaneous intervals. In particular,
using the asymptotic theory of MLE, we note an important result that the limiting co-
variance matrix of the MLE is less than full rank. This result is a key element that
allows us to establish an efficient gate-keeping test with a null reference distribution with
a degrees of freedom ν < G− 1. Without the theory I derived in dissertation, intuitively
one might conjecture a null distribution with G−1 degrees of freedom, which would lead
to a conservative test. As the design structure of a SMART get more complicated, which
usually reflects more intermediate response categories or more stage-specific treatment
options, the formula I derived for calculating the exact degree of freedom can help achieve
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Figure 6.1. An degenerate case of SMART design.
An attractive feature of using the MLE is that the distributional results can be gener-
alized to different types of primary outcomes, such as data with distributions belonging
to exponential family. The proof is included in Appendix 1. For the research of chronic
diseases, such as cancer, the most commonly used primary endpoint is survival outcome.
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In the future, I plan to extend the proposed methods to handle time-to-event data. I have
also shown in the dissertation that the proposed methods can be applied to SMARTs with
varying design structures and randomization schemes, and the performances were evalu-
ated in finite sample settings using simulations. We note that when the design structure
degenerates to an simple case such that only two adaptive interventions were included in
the study, as shown in Figure 6.1, the proposed Wald test is equivalent to a single pair-
wise test described in Chapter 2.3. Another application of the proposed method under
degenerate case see the SMART design in Chapter 5. Under the unbalanced randomiza-
tion scheme, some subgroups of patients may have small randomization probabilities and
thus the weights of estimation built based on the inversed randomization probabilities
can be big. In such cases, the variation of estimation based on IPWE can be inflated due
to the impact of some outlines. While the methods based on MLE is more stable.
A potential limitation of using the MLE is that it requires the full specification of the
model, and it may be perceived as restrictive in application. We however note that under
normality, the MLE is asymptotically identical to the IPWE, which suggests certain ex-
tent of robustness of MLE, at least for continuous outcomes. Furthermore, the proposed
gate-keeping procedure is not tied to MLE. Ogabagaber et al. (2016) for example con-
struct a Wald test based on IPWE. As long as we can obtain a consistent estimator for
the AI value and the asymptotic variance-covariance of these estimators, we will be able
to apply the gate-keeping method. These are certainly topics for further study. Having
said that, the results in my dissertation are derived under rather general conditions on
the distribution of final primary outcome, with the exponential family being the most
prominent example that the theory is applicable to. Thus, the specific procedure studied
in my dissertation have applications in very broad settings potentially.
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In Chapter 4, I developed an R package to provide an user-friendly statistical soft-
ware for users to design SMART and analyze SMART data. The package can be used
for study design, data analysis and data visualization. So far, I considered SMART as
a non-adaptive design, by which the values of design parameters, such as randomization
probabilities, are decided at the design stage. Once the trial begins, the values of these
design parameters do not change throughout the study. Cheung et al. (2015) proposed a
design called Sequential Multiple Assignment Randomization Trial with Adaptive Ran-
domization. Such a design allows clinical trialists to control 3 design parameters based on
the results of interim analysis so as to improve the quality of patient care of a SMART.
As an extension of dissertation research, I plan to add a function that allows the design
parameters to be adapted to the results of interim analysis using the method proposed
in Cheung et al (2015) in the near future.
In Chapter 5, I demonstrated the use of SMART to improve the design efficiency in a
clinical trial for comparing multiple patient care strategies for depression management. I
showed that the randomization probabilities has great impact on the power of SMART.
However, the exact quantitative relationship between randomization probabilities and the
power of SMART given a design structure and targeted parameters of outcomes remains
unclear. In the future, as an extension of the dissertation, I plan to thoroughly examine
this relationship under a general SMART design framework, so that the randomization
probabilities leading to to optimal power can be identified efficiently.
In my dissertation research, I focused on design and analysis of SMART for compar-
ing multiple AIs, which is challenging given the complicated tree structure of SMART
design. The “curse of dimensionality” is a major concern in evaluating AIs embedded in
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SMART, as the total number of AIs embedded in SMART increases exponentially as the
number of stage, intermediate response categories and stage-specific treatment options
increase. The proposed gate-keeping Wald test and the MCB simultaneous intervals are
attractive because they are affected by the number of embedded AIs to a lesser extent
than pairwise comparison methods with multiplicity adjustments. As a further extension
of this research, it will be of interest to develop an adaptive SMART design that can
efficiently use the interim analysis results to simplify the tree structure of SMART so as
to reduce the dimensionality of SMART data and potentially improve the practicality of
SMART design in the world of clinical trial.
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Appendix
Appendix 1: Proof of Theorem
Proof of Theorem 1
We assume that f(y1|φijk, τijk) satisfies the regularity conditions asspecified in Theorem
5.39 of van der Varrt (1998). We first prove (3). Noticing that under the standard
regularity conditions, we have
√
n











where Σpi and Σφi are given in Theorem 1. By the delta-method and using the two

























Before proving (4), we first establish two lemmas.
Lemma 1: Let A and B be two k × k real symmetric matrices. Assume A is positive
definite and B is positive semi-definite. Then,
rank(A+B) = rank(A) = k.




2 , there exist an orthogonal ma-
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CT = diag{λ1, · · · , λk},



















diag{1 + λ1, . . . , 1 + λk}
)
= k.




Kij − Ji + 1 = mi − Ji + 1.
Proof: We apply the principle of mathematical induction to Ji. For such purpose, we
write Ai as Ai(Ki1, . . . , KiJi). If Ji = 2, then
Ai(Ki1, Ki2) =
(
IKi1 ⊗ 1Ki1|1Ki1 ⊗ IKi2
)
,
which, after some elementary operations for block matrices, becomes
 0 0 IKi2
















= Ki2 +Ki1 − 1.
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Since after some elementary operations for block matrices
Ai
(




IKi1 ⊗ 1K′i |1Ki1 ⊗Ai(Ki1, . . . , Ki,Ji+1)
)
becomes  0 0 Ai(Ki2, . . . , Ki,Ji+1)



















Kij − (Ji + 1) + 1,
which proves the claim for Ji + 1.






















Kij − Ji + 1.
103
Proof of Theorem 2
By (3) in Theorem 1, under H0, Q
d−→ χ2ν . By a contiguity argument, under the local
alternatives {Θn} which satisfies (8), Q d−→ χ2ν(λ∗). We now verify that the degrees of
freedom formula (7). Let G =
∑I
i=1Gi and m =
∑I
i=1mi. Define an G×m matrix A as
A = bdiag{Ai; i = 1, . . . , I}.






By subtracting the first row from the remaining (G− 1) rows in A, and then subtracting
the first column from the remaining columns (all of these are elementary operations), A




and check that (0 | B) = CA holds. Then,
rank(A) = 1 + rank(B) = 1 + rank(CA).













Ji + I − 1.
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Proof of Theorem 3
Let g∗ = argmax
1≤i≤G
θi, where ties can be broken in any fashion without affecting the validity
of the proof. Consider
E =
{
θˆi − θi − δg∗σˆig∗/
√
n ≤ θˆg∗ − θg∗ ≤ θˆi − θi + δg∗σˆig∗/
√
n; i 6= g∗
}
.
By the construction of δg∗ ,
lim
n→∞
P (E) = 1− α.
Since
θˆg∗ − θg∗ ≥ θˆi − θi − δg∗σˆig∗/
√
n
for all i 6= g∗ is equivalent to
θˆg∗ − θˆi + δg∗σˆig∗/
√
n ≥ θg∗ − θi ≥ 0
for all i 6= g∗, we conclude that g∗ ∈ B.
From




θi − θg∗ ≤ θˆi − θˆg∗ + δg∗σˆig∗/
√
n,
and noticing that θi − θg∗ ≤ 0, we conclude that
E ⊆
{
g∗ ∈ B, θi − θg∗ ≤ min
{















g∗ ∈ B, θi − θg∗ ≥ θˆi − θˆg∗ − δg∗σˆig∗/
√
















Li ≤ θi − max
1≤j≤G












Li ≤ θi − max
1≤j≤G




P (E) = 1− α.
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Appendix 2. Specification of φijk’s in simulation
We provide an example of generating the sequence-specific mean outcome φijk in the
simulations under design structure 1 (DS1) and balanced randomization scheme (BR)
with value pattern 1 (VP1). There are 8 possible treatment sequences in this setting
and the sequence-specific means φijk can be expressed as a set of linear functions of β as
follows,
φ(111) = β0
φ(112) = β0 + β3
φ(121) = β0 + β2
φ(122) = β0 + β2 + β3 + β6
φ(211) = β0 + β1
φ(212) = β0 + β1 + β3 + β5
φ(221) = β0 + β1 + β2 + β4
φ(222) = β0 + β1 + β2 + β3 + β4 + β5 + β6 + β7.
Also, the value of an AI in this setting can be calculated by
θi;ki1,ki2 = Pi1φi1ki1 + Pi2φi2ki2 ,



















































































β0 + β1 +
1
3
β2 + β3 +
1
3









We added β on the right bottom of Θ∗ in (22) to indicate that the value of Θ∗ only
depends on the values of β. With VP1, we have
θ1;1,1 = θ1;1,2 = θ1;2,1 = θ1;2,2 < θ2;1,1 = θ2;1,2 = θ2;2,1 = θ2;2,2. (23)
From (22) and (23) we know that any set of β satisfying β1 > 0 and β2 = β3 = β4 = β5 =
β6 = β7 = 0 can be used to build a SMART under DS1 and with VP1. Similarly, we can
go further to restrict the values of β under BR and ∆ = 0.05. First, we build the target

















where i, i′, ki1, ki2, ki′1, ki′2 = 1, 2; I{E} = 1 when event E occurs and I{E} = 0 otherwise.
The value of I{.} in (24) changes according to the relationship between two AIs of di;ki1,ki2
and di′;ki′1,ki′2 . For example, when two AIs are complete overlapped, we have I{Ti =
Ti′} = I{Si1ki1 = Si′1ki′1} = I{Si2ki2 = Si′2ki′2} = 1 so that (24) is the variance of
an AI. Meanwhile, when both AIs suggest the same stage-1 treatment, but different
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treatments for either responders or non-responders at stage 2, we have I{Ti = Ti′} = 1
and I{Si1ki1 = Si′1ki′1} = I{Si2ki2 = Si′2ki′2} = 0. In this way, we can calculate all the
elements of target Σ∗ in (9) by 8 × 8 known functions of {pii, piijk, Pi1, Pi2, φijk, σijk}. In





) and σijk = 10, for i, j, k = 1, 2, so





T )−(CΘ∗β) = 0.05, (25)
where the contras matrix
C =

1 −1 0 0 0 0 0 0
1 0 −1 0 0 0 0 0
1 0 0 −1 0 0 0 0
1 0 0 0 −1 0 0 0
1 0 0 0 0 −1 0 0
1 0 0 0 0 0 −1 0
1 0 0 0 0 0 0 −1

.
By solving (25), we obtained a set of β = (0, 4.47, 0, 0, 0, 0, 0, 0), which were used to
simulate the SMART data under DS1 and BR, with VP1 and ∆ = 0.05. In each simulated
SMART data based on β = (0, 4.47, 0, 0, 0, 0, 0, 0), there were 8 possible sequences and
the sequences-specific means were Φ = (0, 0, 0, 0, 4.7, 4.7, 4.7, 4.7). The solution of target
equation (25) is not unique, since β0 can take any value of (−∞,+∞). However with
the goal of simulating a SMART with desired features, any set of β satisfying (25) can
be selected to use. We adopted β0 = 0 in the simulation. The values of β’s for all the
scenarios in the simulations are provided in the table 2.3.
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